<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        426-212-19
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        BANORIV 10 mg Film Coated Tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        RIVAROXABAN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        71.30
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SPIMACO" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 488]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SPIMACO ADDWAEIH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        B01AX06
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Banoriv contains the active substance rivaroxaban and is used in adults to &bull; Prevent blood clots in the veins after a hip or knee replacement operation. Your doctor has prescribed this medicine for you because after an operation you are at an increased risk of getting blood clots. &bull; Treat blood clots in the veins of your legs (deep vein thrombosis) and in the blood vessels of your lungs (pulmonary embolism), and to prevent blood clots from reoccurring in the blood vessels of your legs and/or lungs. Banoriv belongs to a group of medicines called antithrombotic agents. It works by blocking a blood clotting factor (factor Xa) and thus reducing the tendency of the blood to form clots.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Banoriv</strong></p><p>&bull; if you are allergic to rivaroxaban or any of the other ingredients of this medicine (listed in section 6)</p><p>&bull; if you are bleeding excessively</p><p>&bull; if you have a disease or condition in an organ of the body that increases the risk of serious bleeding (e.g. stomach ulcer, injury or bleeding in the brain, recent surgery of the brain or eyes)</p><p>&bull; if you are taking medicines to prevent blood clotting (e.g. warfarin, dabigatran, apixaban or heparin), except when changing anticoagulant treatment or while getting heparin through a venous or arterial line to keep it open</p><p>&bull; if you have a liver disease which leads to an increased risk of bleeding</p><p>&bull; if you are pregnant or breast feeding Do not take Banoriv and tell your doctor if any of these apply to you.</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist before taking Banoriv.</p><p><strong>Take special care with Banoriv</strong></p><p>&bull; if you have an increased risk of bleeding, as could be the case in situations such as:</p><p>&minus; moderate or severe kidney disease, since your kidney function may affect the amount of medicine that works in your body</p><p>&minus; if you are taking other medicines to prevent blood clotting (e.g. warfarin, dabigatran, apixaban or heparin), when changing anticoagulant treatment or while getting heparin through a venous or arterial line to keep it open (see section &ldquo;Other medicines and Banoriv&rdquo;)</p><p>&minus; bleeding disorders</p><p>&minus; very high blood pressure, not controlled by medical treatment</p><p>&minus; diseases of your stomach or bowel that might result in bleeding, e.g. inflammation of the bowels or stomach, or inflammation of the oesophagus (gullet) e.g. due to gastroesophageal reflux disease (disease where stomach acid goes upwards into the oesophagus)</p><p>&minus; a problem with the blood vessels in the back of your eyes (retinopathy)</p><p>&minus; a lung disease where your bronchi are widened and filled with pus (bronchiectasis), or previous bleeding from your lung</p><p>&nbsp;&bull; if you have a prosthetic heart valve</p><p>&bull; if your doctor determines that your blood pressure is unstable or another treatment or surgical procedure to remove the blood clot from your lungs is planned.</p><p><strong>If any of the above apply to you</strong>, tell your doctor before you take Banoriv. Your doctor will decide, if you should be treated with this medicine and if you should be kept under closer observation. If you need to have an operation: it is very important to take Banoriv before and after the operation exactly at the times you have been told by your doctor.</p><p>&nbsp;</p><p>If your operation involves a catheter or injection into your spinal column (e.g. for epidural or spinal anaesthesia or pain reduction):</p><p>&bull; it is very important to take Banoriv exactly at the times you have been told by your doctor</p><p>&bull; tell your doctor immediately if you get numbness or weakness of your legs or problems with your bowel or bladder after the end of anaesthesia, because urgent care is necessary.</p><p><strong>Children and adolescents</strong></p><p>Banoriv is not recommended for people under 18 years of age. There is not enough information on its use in children and adolescents. Other medicines and Banoriv Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.</p><p><strong>&bull; If you are taking: </strong></p><p>&bull; some medicines for fungal infections (e.g. ketoconazole, itraconazole, voriconazole, posaconazole), unless they are only applied to the skin</p><p>&bull; some anti-viral medicines for HIV / AIDS (e.g. ritonavir) &bull;</p><p>other medicines to reduce blood clotting (e.g. enoxaparin, clopidogrel or vitamin K antagonists such as warfarin and acenocoumarol)</p><p>&bull; anti-inflammatory and pain relieving medicines (e.g. naproxen or acetylsalicylic acid)</p><p>&bull; dronedarone, a medicine to treat abnormal heart beat</p><p>&bull; some medicines to treat depression (selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs))</p><p>If any of the above apply to you, tell your doctor before taking Banoriv, because the effect of Banoriv may be increased. Your doctor will decide, if you should be treated with this medicine and if you should be kept under closer observation. If your doctor thinks that you are at increased risk of developing stomach or bowel ulcers, he may also use a preventative ulcer treatment.</p><p>&bull; If you are taking:</p><p>&bull; some medicines for treatment of epilepsy (phenytoin, carbamazepine, phenobarbital)</p><p>&bull; St John&rsquo;s Wort (Hypericum perforatum), a herbal product used for depression</p><p>&bull; rifampicin, an antibiotic</p><p><strong>If any of the above apply to you</strong>, tell your doctor before taking Banoriv, because the effect of Banoriv may be reduced. Your doctor will decide, if you should be treated with Banoriv and if you should be kept under closer observation.</p><p><strong>Pregnancy and breast feeding</strong></p><p>Do not take Banoriv if you are pregnant or breast feeding. If there is a chance that you could become pregnant, use a reliable contraceptive while you are taking Banoriv. If you become pregnant while you are taking this medicine, tell your doctor immediately, who will decide how you should be treated.</p><p><strong>Driving and using machines </strong></p><p>Banoriv may cause dizziness (common side effect) or fainting (uncommon side effect) (see section 4 &lsquo;Possible side effects&rsquo;). You should not drive or use machines if you are affected by these symptoms.</p><p><strong>Banoriv contains lactose </strong></p><p>If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p><strong>How much to take</strong></p><p>&bull; To prevent blood clots in the veins after a hip or knee replacement operation The recommended dose is one tablet Banoriv 10 mg once a day</p><p>. &bull; To treat blood clots in the veins of your legs and blood clots in the blood vessels of your lungs, and for preventing blood clots from re-occurring, After at least 6 months blood clot treatment, the recommended dose is either one 10 mg tablet once a day or one 20 mg tablet once a day. )</p><p>Your doctor has prescribed you Banoriv 10 mg once a day (. Swallow the tablet preferably with water. Banoriv can be taken with or without food. If you have difficulty swallowing the tablet whole, talk to your doctor about other ways to take Banoriv.</p><p>The tablet may be crushed and mixed with water or apple puree immediately before you take it. If necessary, your doctor may also give you the crushed Banoriv tablet through a stomach tube</p><p>&nbsp;</p><p><strong>When to take Banoriv</strong></p><p>Take the tablet every day until your doctor tells you to stop.</p><p>Try to take the tablet at the same time every day to help you to remember it.</p><p>Your doctor will decide how long you must continue treatment.</p><p>To prevent blood clots in the veins after a hip or knee replacement operation:</p><p>Take the first tablet 6 - 10 hours after your operation.</p><p>If you have had a major hip operation you will usually take the tablets for 5 weeks.</p><p>If you have had a major knee operation you will usually take the tablets for 2 weeks.</p><p>&nbsp;</p><p><strong>If you take more Banoriv than you should</strong></p><p>Contact your doctor immediately</p><p><strong>if you have taken too many Banoriv tablets</strong>.</p><p>Taking too much Banoriv increases the risk of bleeding.</p><p><strong>If you forget to take Banoriv </strong></p><p>If you have missed a dose, take it as soon as you remember. Take the next tablet on the following day and then carry on taking a tablet once a day as normal. Do not take a double dose to make up for a forgotten tablet.</p><p><strong>If you stop taking Banoriv</strong></p><p>Do not stop taking Banoriv without talking to your doctor first, because Banoriv prevents the development of a serious condition. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Banoriv can cause side effects, although not everybody gets them.</p><p>Like other similar medicines (antithrombotic agents), Banoriv may cause bleeding which may potentially be life threatening. Excessive bleeding may lead to a sudden drop in blood pressure (shock). In some cases the bleeding may not be obvious.</p><p><strong>&nbsp;Possible side effects which may be a sign of bleeding:</strong></p><p>Tell your doctor immediately, if you experience any of the following side effects:</p><p>&bull; long or excessive bleeding</p><p>&bull; exceptional weakness, tiredness, paleness, dizziness, headache, unexplained swelling, breathlessness, chest pain or angina pectoris, which may be signs of bleeding.</p><p>Your doctor may decide to keep you under closer observation or change how you should be treated.</p><p>Possible side effects which may be a sign of severe skin reaction:</p><p>Tell your doctor immediately if you experience skin reactions such as spreading intense skin rash, blisters or mucosal lesions, e.g. in the mouth or eyes (Stevens-Johnson syndrome/Toxic Epidermal Necrolysis). The frequency of this side effect is very rare (less than 1 in 10,000).</p><p><strong>Overall list of possible side effects:</strong></p><p><strong>Common (may affect up to 1 in 10 people):</strong> &bull; bleeding in the stomach or bowel, urogenital bleeding (including blood in the urine and heavy menstrual bleeding), nose bleed, bleeding in the gum &bull; bleeding into the eye (including bleeding from the whites of the eyes) &bull; bleeding into tissue or a cavity of the body (haematoma, bruising) &bull; coughing up blood &bull; bleeding from the skin or under the skin &bull; bleeding following an operation &bull; oozing of blood or fluid from surgical wound&nbsp;&bull; swelling in the limbs &bull; pain in the limbs &bull; fever &bull; reduction in red blood cells which can make the skin pale and cause weakness or breathlessness &bull; stomach ache, indigestion, feeling or being sick, constipation, diarrhoea &bull; low blood pressure (symptoms may be feeling dizzy or fainting when standing up) &bull; decreased general strength and energy (weakness, tiredness), headache, dizziness &bull; rash, itchy skin &bull; impaired function of the kidneys (may be seen in tests performed by your doctor) &bull; blood tests may show an increase in some liver enzymes</p><p>&nbsp;</p><p><strong>Uncommon (may affect up to 1 in 100 people): </strong>&bull; bleeding into the brain or inside the skull &bull; bleeding into a joint causing pain and swelling &bull; fainting &bull; feeling unwell &bull; dry mouth &bull; faster heartbeat &bull; allergic reactions, including allergic skin reactions &bull; hives &bull; impaired function of the liver (may be seen in tests performed by your doctor) &bull; blood tests may show an increase in bilirubin, some pancreatic or liver enzymes or in the number of platelets</p><p><strong>Rare (may affect up to 1 in 1,000 people): </strong>&bull; bleeding into a muscle &bull; localised swelling&nbsp;&bull; yellowing of the skin and eye (jaundice) &bull; collection of blood (haematoma) in the groin as a complication of the cardiac procedure where a catheter is inserted in your leg artery (pseudoaneurysm)</p><p>&nbsp;</p><p><strong>Not known (frequency cannot be estimated from the available data):</strong> &bull; increased pressure within muscles of the legs or arms after a bleeding, which leads to pain, swelling, altered sensation, numbness or paralysis (compartment syndrome after a bleeding) &bull; kidney failure after a severe bleeding The following side effects have been reported since authorisation: &bull; Angioedema and allergic oedema (swelling of the face, lips, mouth, tongue or throat) &bull; Cholestasis (decreased bile flow), Hepatitits incl. hepatocellular injury (inflamed liver incl. liver injury) &bull; Thrombocytopenia (low number of platelets, which are cells that help blood to clot).</p><p>&nbsp;</p><p>Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Store below 30&deg;C Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the carton and on each blister after EXP. The expiry date refers to the last day of that month. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; The active substance is rivaroxaban. Each tablet contains 10 mg of rivaroxaban.</p><p>&bull; The other ingredients are: Tablet core:&nbsp;</p><p>&minus; Lactose BP 200,Avicel PH 101,Hydroxypropyl Methylcellulose,Sodium Lauryl Sulphate,Croscarmellose Sodium Type-A,Magnesium Stearate. Tablet film coat: &minus; Hydroxypropyl Methyl Cellulose,Titanium Dioxide Pharma Grade,Purified Talc,Polyethylene Glycol MW 6000,Iron Oxide Red,Purified Water BP</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Pink to dark pink coloured, round, biconvex, film-coated tablet, engraved with “262” on one
side and plain on the other side.
Each pack contains 10 film coated tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>SPIMACO AlQassim pharmaceutical plant Saudi Pharmaceutical Industries &amp; Medical Appliance Corporation.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Saudi Arabia This leaflet was last revised in June 2018
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يحتوي بانوريڤ على المادة الفعالة ريفاروكسيبان وتستخدم في البالغين في: &minus; لمنع تجلط الدم في األوردة بعد عملية استبدال الورك أو الركبة . وقد وصف الطبيب لك هذا الدواء ألنه بعد العملية يزيد خطر تكون جلطات الدم. &minus; عالج جلطات الدم في أوردة ساقيك )تجلط األوردة العميقة ( وفي األوعية الدموية في رئتيك )انسداد رئوي(، ولمنع جلطات الدم من إعادة التكون في األوعية الدموية في الساقين و / أو الرئتين. بانوريڤ ينتمي إلى مجموعة من األدوية تسمى مضادات التجلطات. وهو يعمل عن طريق منع عامل تخثر الدم )عامل رقم عشرة(، وبالتالي الحد من ميل الدم إلى تشكيل جلطات.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>ال تتناول بانوريڤ</strong></p><p>&bull; إذا كان لديك حساسية من ريفاروكسيبان أو أي من المكونات األخرى من هذا الدواء )المدرجة في القسم 6 )</p><p>&bull; إذا كنت ت نزف بشكل مفرط</p><p>&bull; إذا كان لديك مرض أو حالة في أحد أجهزة الجسم الذي يزيد من خطر النزيف الشديد )مثل قرحة المعدة أو إصابة أو نزيف في الدماغ، جراحة حديثة في الدماغ أو العينين(</p><p>&bull; إذا كنت تتناول أدوية لمنع تخثر الدم )مثل الوارفارين، دابي جاتران، ابيكسابان أو الهيبارين(، إال في حالة تغيير العالج المضاد للتخثر أو في حالة اعطاء الهيبارين من خالل الوريد أو الشريان إلبقائها مفتوحة.</p><p>&bull; إذا كان لديك مرض في الكبد مما يؤدي إلى زيادة خطر النزيف&nbsp;</p><p>&bull; إذا كنت من الحوامل أو المرضعات.</p><p>ال تأخذ بانوريڤ <strong>وأخبر طبيبك إذا كان أي من هذه تنطبق عليك</strong>. التحذيرات واالحتياطات أخبر طبيبك أو الصيدالني قبل تناول بانوريڤ&nbsp;</p><p><strong>أعطي عناية خاصة مع بانوريڤ&nbsp;</strong></p><p><strong>&bull; إذا كان لديك زيادة خطر النزيف، كما يمكن أن يكون هذا هو الحال في حاالت مثل: &minus;</strong></p><p>أمراض الكلى الحادة أو المتوسطة، حيث أن وظيفة الكلى الخاصة بك قد تؤثر على كمية الدواء التي تعمل في جسمك &minus; إذا كنت تأخذ أدوية أخرى لمنع تخثر الدم )مثل الوارفارين، دابي جاتران، ابيكسيبان أو الهيبارين(، عند تغيير العالج المضاد للتخثر أو في حالة اعطاء الهيبارين من خالل الوريد أو الشريان إلبقائها مفتوحة. )انظر فقرة &quot;األدوية األخرى وبانوريڤ &quot;( &minus; اضطرابات النزيف &minus; ارتفاع شديد في ضغط الدم، الغير مستجيب للعالج &minus; أمراض المعدة أو األمعاء التي قد تؤدي إلى نزيف، مثل التهاب األمعاء أو المعدة، أو التهاب في المريء على سبيل المثال بسبب مرض االرتجاع المعدي المريئي )حيث يرتد حمض المعدة صعودا إلى المريء( &minus; مشكلة في األوعية الدموية في الجزء الخلفي من العين )اعتالل الشبكية( &minus; احد أمراض الرئة حيث ت تسع القصبات و تمتلئ بالقيح، أو نزيف سابق من الرئة.</p><p><strong>&bull; إذا كان لديك صمام قلب صناعي</strong></p><p><strong>&bull; إذا قرر طبيبك أن ضغط دمك غير مستقر أو قرر وصف أي عالج آخر أو إجراء جراحي إلزالة خثرة الدم من الرئتين</strong></p><p>إذا كان أي من أعاله ينطبق عليك، أخبر طبيبك قبل أن تتناول بانوريڤ . سوف يقرر الطبيب،</p><p>إذا كان يجب أن تتناول هذا الدواء أم ال، وإذا كان يجب أن تبقى تحت المالحظة األدق. إذا كنت بحاجة إلى إجراء عملية جراحية: من المهم جدًا تناول بانوريڤ قبل العملية وبعدها في األوقات التي أخبرك بها طبيبك بالضبط. إذا تضمنت العملية الخاصة بك قسطرة أو الحقن في العمود الفقري الخاص بك )على سبيل المثال للتخدير فوق الجافية أو العمود الفقري أو الحد من األلم(: o من المهم جدا أن تأخذ بانوريڤ تماما في األوقات التي أخبرك بها الطبيب o أخبر طبيبك فورا إذا كان لديك خدر أو ضعف الساقين أو مشاكل في األمعاء أو المثانة بعد انتهاء التخدير الخاص بك، ألن الرعاية العاجلة في هذه الحالة أمر ضروري</p><p><strong>األطفال والمراهقين </strong></p><p><strong>ال ينصح بتناول بانوريڤ لمن هم دون 18 سنة من العمر. </strong>ليست هناك معلومات كافية عن استخدامه في األطفال والمراهقين. األدوية األخرى و بانوريڤ أخبر طبيبك أو الصيدلي إذا كنت تتناول، قد تناولت مؤخرا أو قد تتناول أي أدوية أخرى، بما في ذلك األدوية التي تم الحصول عليها دون وصفة طبية.&nbsp;</p><p>&nbsp;</p><p><strong>&bull; إذا كنت تتناول:</strong></p><p>&bull; بعض األدوية لألمراض الفطرية )مثل الكيتوكونازول، االيتراكونازول، فوريكونازول، بوساكونازول (، ما لم يتم وضعها على الجلد فقط &bull; بعض األدوية المضادة للفيروسات لعالج فيروس نقص المناعة البشرية / اإليدز )على سبيل المثال ريتونافير( &bull; أدوية أخرى لتقليل تخثر الدم )مثل اينوكسابارين، كلوبيدوجرل أو مضادات فيتامين K مثل الوارفارين وأسينوكومارول( &bull; األدوية المضادة لاللتهابات وتخفيف األلم )مثل نابروكسين أو حمض استل ساليسالت ( &bull; دروندارون ، وهو دواء لعالج ضربات القلب الغير طبيعية &bull; بعض األدوية لعالج االكتئاب )مثبطات إعادة امتصاص السيروتونين االنتقائية ،مثبطات إعادة إمتصاص السيروتونين والنورإيبنفرين(.</p><p>إذا كان أي من أعاله ينطبق عليك، أخبر طبيبك قبل تناول بانوريڤ ، ألن تأثير بانوريڤ قد يزيد. سوف يقرر الطبيب، إذا كان يجب أن تتناول هذا الدواء، وإذا كان يجب أن تبقى تحت المالحظة األدق . وإذا كان الطبيب يعتقد ان ك في خطر متزايد لحدوث قرحة المعدة أو األمعاء، يمكن أيضا أن ينصحك ب استخدام عالج قرحة وقائية.&nbsp;</p><p><strong>&bull; إذا كنت تتناول:</strong></p><p>&bull; بعض األدوية لعالج الصرع )الفينيتوين، كاربامازيبين، الفينوباربيتال( &bull; سانت جون ورت ، وهو منتج عشبي يستخدم لعالج االكتئاب &bull; ريفامبيسين، وهو مضاد حيوي</p><p>إذا كان أي من أعاله ينطبق عليك، أخبر طبيبك قبل تناول بانوريڤ ، ألن تأثير بانوريڤ ربما ينخفض. سوف يقرر الطبيب، إذا كان يجب أن تتناول بانوريڤ وإذا كان يجب أن تبقى تحت المالحظة األدق.&nbsp;</p><p><strong>الحمل والرضاعة الطبيعية</strong></p><p>ال تتناولي بانوريڤ إذا كنت من الحوامل أو المرضعات. إذا كان هناك فرصة أن تصبحي حامال، استخدمي وسائل منع الحمل يمكن االعتماد عليها أثناء العالج ب بانوريڤ . إذا أصبحت حامال في أثناء تناول هذا الدواء، أخبر ي طبيبك فورا، سيقرر كيف يجب أن تتم معالجتك.</p><p><strong>القيادة و استخدام آالت</strong></p><p>بانوريڤ قد يسبب دوخة )عرض جانبي شائع( أو اإلغماء )عرض جانبي غير شائع( )انظر القسم 4&quot; .األعراض الجانبية المحتملة &quot; (. يجب أن ال تقود أو تستخدم اآلالت إذا كنت تعاني من هذه األعراض.</p><p><strong>يحتوي بانوريڤ على الالكتوز</strong></p><p>إذا قيل لك من قبل الطبيب أن لديك عدم تحمل لبعض السكريات، اخبر الطبيب قبل تناول هذا الدواء.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>دائما تناول هذا الدواء تماما كما أخبرك طبيبك. استشر طبيبك أو الصيدلي إذا لم تكن متأكدا.</p><p><strong>الجرعة</strong></p><p>&bull; لمنع تجلط الدم في األوردة بعد عملية استبدال الورك أو الركبة الجرعة الموصى بها هي قرص واحد بانوريڤ 10 ملجم مرة واحدة في اليوم. &bull; لعالج جلطات الدم في أوردة ساقيك وجلطات الدم في األوعية الدموية في رئتيك، ولمنع إعادة تكوين الجلطات الدموي ة بعد 6 أشهر على األقل من عالج الجلطة الجرعة الموصى بها هي إما قرص 10 ملجم مرة واحدة في اليوم أو قرص 20 ملجم مرة واحدة في اليوم. )لقد وصف لك طبيبك بانوريڤ 10 ملجم مرة في اليوم(. يفضل تناول القرص مع الماء. يمكن تناول بانوريڤ مع أو بدون الطعام. إذا كان لديك صعوبة في بلع قرص بأكمله، أخبر طبيبك حول طرق أخرى لتناول بانوريڤ . يمكن سحق الحبوب وخلطها مع الماء أو هريس التفاح على الفور قبل التناول. إذا لزم األمر، فإن طبيبك قد يعطيك أيضا قرص بانوريڤ مسحوق من خالل أنبوب في المعدة.</p><p><strong>متى تتناول بانوريڤ</strong></p><p>تناول القرص كل يوم حتى يخبرك طبيبك بالتوقف. حاول أن تتناول القرص في نفس الوقت كل يوم لمساعدتك على تذكره. سيحدد الطبيب المدة التي يجب عليك مواصلة العالج فيها. لمنع تجلط الدم في األوردة بعد عملية استبدال الورك أو الركبة : تناول القرص األول بعد 6 - 10 ساعات من العملية. إذا كانت عملية كبيرة خاصة بالورك، عادة يتم تناول األقراص لمدة 5 أسابيع. إذا كانت عملية كبيرة خاصة بالركبة، عادة يتم تناول األقراص لمدة أسبوعين.</p><p><strong>إذا تناولت بانوريڤ أكثر مما يجب</strong></p><p>اتصل بطبيبك على الفور إذا كنت قد تناولت الكثير من أقراص بانوريڤ . أخذ الكثير من أقراص بانوريڤ يزيد من خطر النزيف.</p><p><strong>ذا كنت قد نسيت أن تتناول بانوريڤ</strong></p><p>إذا نسيت تناول جرعة، تناولها في أقرب وقت ممكن حينما تتذكر. تناول القرص التالي في اليوم التالي واستمر في تناول قرص واحد في اليوم كالمعتاد. ال تتناول قرصين معا لتعويض القرص المنسي.</p><p><strong>إذا توقفت عن تناول بانوريڤ</strong></p><p>ال تتوقف عن تناول بانوريڤ دون التحدث مع طبيبك أوال، ألن بانوريڤ يعالج ويمنع حالة خطيرة. إذا كان لديك أي أسئلة أخرى عن استخدام هذا الدواء، اسأل طبيبك أو الصيدلي</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع األدوية، يمكن أن ي تسبب بانوريڤ في أعراض جانبية، على الرغم من أن الجميع ال يتعرض لها. مثل أدوية أخرى مماثلة )مضادات التجلط(، قد ي سبب بانوريڤ النزيف الذي من المحتمل أن ي كون مهدد للحياة. النزيف الحاد قد يؤدي إلى انخفاض مفاجئ في ضغط الدم )صدمة(. في بعض الحاالت قد ال يكون نزيف واضح.&nbsp;</p><p><strong>األعراض الجانبية المحتملة التي قد تكون عالمة على حدوث نزيف:</strong> أخبر طبيبك فورا إذا كنت تواجه أي من األعراض الجانبية التالية:</p><p>&nbsp;</p><p>&nbsp;</p><p>&bull; النزيف الطويل أو المفرط &bull; ضعف استثنائي، والتعب، وشحوب، والدوخة، والصداع، والتورم الغير مبرر، وضيق في التنفس، ألم في الصدر أو الذبحة الصدرية، والتي قد تكون عالمات النزيف. طبيبك قد ي قرر إبقائك تحت المالحظة الدقيقة أو تغيير طريقة العالج.</p><p>األعراض الجانبية المحتملة التي قد تكون عالمة على رد فعل جلدي تحسسي خطير:&nbsp;</p><p>خبر طبيبك فورا إذا تعرضت ألعراض جلدية مثل انتشار الطفح الجلدي الشديد، البثور أو جروح في األغشية المخاطية، على سبيل المثال. في الفم أو العينين )متالزمة ستيفنز جونسون / انحالل البشرة النخري السمي(. نسبة حدوث هذا العرض الجانبي نادر جدا )أقل من 1 في 10000&nbsp;</p><p>&nbsp;</p><p><strong>القائمة الشاملة لل عراض الجانبية المحتملة: </strong></p><p><strong>شائع )قد يؤثر على ما يصل إلى 1 في كل 10 أشخاص (</strong>:</p><p>&bull; نزيف في المعدة أو األمعاء، نزيف في الجهاز البولي التناسلي )بما في ذلك الدم في البول ونزيف الحيض الشديد(، نزيف األنف، ونزيف في اللثة &bull; نزيف في العين )بما في ذلك نزيف من بياض العينين( &bull; نزيف في األنسجة أو تجويف في ال جسم )ورم دموي، وكدمات( &bull; سعال الدم &bull; نزيف من الجلد أو تحت الجلد &bull; نزيف بعد العملية &bull; رشح الدم أو السوائل من الجروح &bull; تورم في األطراف &bull; ألم في األطراف &bull; حمى &bull; انخفاض في خاليا الدم الحمراء التي يمكن أن تجعل الجلد شاحب وتسبب ضعف أو ضيق في التنفس &bull; ألم في المعدة، عسر الهضم، والشعور بالغثيان، واإلمساك، واإلسهال &bull; انخفاض ضغط الدم )األعراض: قد تشمل الشعور بالدوار أو اإلغماء عند الوقوف(&nbsp;&bull; انخفاض القوة العامة والطاقة )الضعف، التعب(، والصداع، والدوخة &bull; طفح جلدي، حكة في الجلد &bull; ضعف في وظائف الكلى )يمكن أن ينظر إليها في االختبارات التي يقوم بها الطبيب( &bull; قد تظهر اختبارات الدم زيادة في بعض إنزيمات الكبد.</p><p><strong>غير شائع )قد يؤثر على ما يصل إلى 1 في كل 100 شخص(:</strong></p><p>&bull; نزيف في الدماغ أو داخل الجمجمة &bull; نزيف في المفاصل مما يسبب األلم والتورم &bull; إغماء &bull; اإلحساس بشعور المرض &bull; جفاف الفم &bull; تسارع نبضات القلب &bull; أمراض الحساسية، بما في ذلك ردود فعل حساسية الجلد &bull; الشري &bull; خلل في وظائف الكبد )يمكن أن ينظر إليها في االختبارات التي يقوم بها الطبيب( &bull; قد تظهر اختبارات الدم زيادة في البيليروبين، وبعض انزيمات البنكرياس أو الكبد أو في عدد الصفائح الدموية.</p><p><strong>نادر )قد يؤثر على ما يصل إلى 1 في كل 1000 شخص(</strong>:</p><p>&bull; نزيف في العضل &bull; تورم موضعي &bull; اصفرار الجلد والعين )اليرقان( &bull; ت جمع الدم )ورم دموي( في الفخذ نتيجة مضاعفات عمليات القلب حيث يتم إدخال قسطرة في شريان ساقك.<strong> </strong></p><p><strong>غير معروف )ال يمكن تقدير مدي حدوثها من البيانات المتاحة(: </strong></p><p>&bull; زيادة الضغط داخل عضالت الساقين والذراعين بعد النزيف، األمر الذي يؤدي إلى األلم، وتورم، وتغير اإلحساس أو التنميل أو الشلل )متالزمة الحيز بعد النزيف( &bull; الفشل الكلوي بعد نزيف حاد.&nbsp;</p><p>تم اإلبالغ عن األعراض الجانبية التالية منذ التسجيل: &bull; وذمة وعائية و وذمة تحسسيه )تورم في الوجه والشفتين والفم واللسان أو الحلق( &bull; ركود صفراوي )انخفض تدفق الصفراء(، التهاب الكبد نتيجة إصابة الخاليا الكبدية )التهاب الكبد بما في ذلك إصابة الكبد( &nbsp;&bull; نقص الصفيحات )انخفاض عدد الصفائح الدموية، وهي الخاليا التي تساعد على تجلط الدم(.</p><p><strong>اإلبالغ عن األعراض الجانبية </strong></p><p>إذا كان لديك أي أعراض جانبية، أخبر طبيبك أو الصيدلي. ويشمل ذلك أي أعراض جانبية محتملة غير المدرجة في هذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحفظ في درجة حرارة تقل عن 30 درجة مئوي ة. حافظ على هذا الدواء بعيدا عن نظر ومتناول األطفال. ال تستخدم هذا الدواء بعد تاريخ انتهاء الصالحية المطبوع على الكرتون وعلى كل شريط بعد كلمة EXP . تاريخ انتهاء الصالحية يشير إلى اليوم األخير من ذلك الشهر. ال تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية.</p><p>اسأل الصيدلي عن كيفية التخلص من األدوية التي لم تعد تستخدم. ومن شأن هذه التدابير أن تساعد في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&bull; المادة الفعالة هي ريفاروكسيبان. كل قرص يحتوي على 10 ملجم من ريفاروكسيبان. &bull;</p><p>المكونات األخرى هي:</p><p>نواة القرص: الكتوز 200 ،افيسيل بي اتش 101 ،هيدروكسي بروبيل ميثيل السيليلوز، صوديوم لوريل سلفيت، كروس كارميلوز صوديو نوع A ، ماغنسيوم ستيرات. الغالف الرقيق: هيدروكسي بروبيل ميثيل السيليلوز، تيتانيوم ثنائي األكسدة ، تلك منقي، بولي ايثيلين جليكول ام دبليو 6000 ، أكسيد الحديد األحمر، ماء نقي.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>أقراص وردية إلى وردية داكنة، مستديرة، محدبة الوجهين، مغلفة بطبقة رقيقة، منقوش عليها رقم &quot; 262 &quot; من احدي الجوانب وجلية السطح على الجانب األخر. تحتوي كل عبوة على 10 أقراص مغلفة بطبقة رقيقة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>مالك الحقوق التسويقية و المصنع الدوائية مصنع األدوية بالقصيم، الشركة السعودية للصناعات الدوائية والمستلزمات الطبية، المملكة العربية السعودية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة في يونيو 2018
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Banoriv 10 mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains 10 mg rivaroxaban.
Excipient with known effect:
Each film-coated tablet contains 89 mg lactose, see section 4.4.
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet (tablet).
Pink to dark pink coloured, round, biconvex, film-coated tablet, engraved with “262” on one side and plain on the other side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery.</p><p>Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients.)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p><em>Prevention of VTE in adult patients undergoing elective hip or knee replacement surgery</em></p><p>The recommended dose is 10 mg rivaroxaban taken orally once daily. The initial dose should be taken 6 to 10 hours after surgery, provided that haemostasis has been established.</p><p>The duration of treatment depends on the individual risk of the patient for venous thromboembolism which is determined by the type of orthopaedic surgery.</p><p>&bull; For patients undergoing major hip surgery, a treatment duration of 5 weeks is recommended.</p><p>&bull; For patients undergoing major knee surgery, a treatment duration of 2 weeks is recommended.</p><p>If a dose is missed the patient should take Banoriv immediately and then continue the following day with once daily intake as before.</p><p><em>Treatment of DVT, treatment of PE and prevention of recurrent DVT and PE</em></p><p>The recommended dose for the initial treatment of acute DVT or PE is 15 mg twice daily for the first three weeks followed by 20 mg once daily for the continued treatment and prevention of recurrent DVT and PE.</p><p>Short duration of therapy (at least 3 months) should be considered in patients with DVT or PE provoked by major transient risk factors (i.e. recent major surgery or trauma). Longer duration of therapy should be considered in patients with provoked DVT or PE not related to major transient risk factors, unprovoked DVT or PE, or a history of recurrent DVT or PE.</p><p>When extended prevention of recurrent DVT and PE is indicated (following completion of at least 6 months therapy for DVT or PE), the recommended dose is 10 mg once daily. In patients in&nbsp;<u>whom</u>&nbsp;the risk of recurrent DVT or PE is considered high, such as those with complicated comorbidities, or who have developed recurrent DVT or PE on extended prevention with Banoriv 10 mg once daily, a dose of Banoriv 20 mg once daily should be considered.</p><p>The duration of therapy and dose selection should be individualised after careful assessment of the treatment benefit against the risk for bleeding (see section 4.4).</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Time Period</p></td><td style="vertical-align:top"><p>Dosing schedule</p></td><td style="vertical-align:top"><p>Total daily dose</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Treatment and prevention of recurrent DVT and PE</p></td><td style="vertical-align:top"><p>Day 1-21</p></td><td style="vertical-align:top"><p>15 mg twice daily</p></td><td style="vertical-align:top"><p>30 mg</p></td></tr><tr><td style="vertical-align:top"><p>Day 22 onwards</p></td><td style="vertical-align:top"><p>20 mg once daily</p></td><td style="vertical-align:top"><p>20 mg</p></td></tr><tr><td style="vertical-align:top"><p>Prevention of recurrent DVT and PE</p></td><td style="vertical-align:top"><p>Following completion of at least 6 months therapy for DVT or PE</p></td><td style="vertical-align:top"><p>10 mg once daily or 20 mg once daily</p></td><td style="vertical-align:top"><p>10 mg or 20 mg</p></td></tr></tbody></table><p>To support the dose switch from 15 mg to 20 mg after Day 21 a first 4 weeks treatment initiation pack of Banoriv for treatment of DVT/PE is available (see section 6.5).</p><p>If a dose is missed during the 15 mg twice daily treatment phase (day 1 - 21), the patient should take Banoriv immediately to ensure intake of 30 mg Banoriv per day. In this case two 15 mg tablets may be taken at once. The patient should continue with the regular 15 mg twice daily intake as recommended on the following day.</p><p>If a dose is missed during the once daily treatment phase, the patient should take Banoriv immediately, and continue on the following day with the once daily intake as recommended. The dose should not be doubled within the same day to make up for a missed dose.</p><p><em>Converting from Vitamin K Antagonists (VKA) to Banoriv</em></p><p>For patients treated for DVT, PE and prevention of recurrence, VKA treatment should be stopped and Banoriv therapy should be initiated once the INR is &le; 2.5.</p><p>When converting patients from VKAs to Banoriv, International Normalized Ratio (INR) values will be falsely elevated after the intake of Banoriv. The INR is not valid to measure the anticoagulant activity of Banoriv, and therefore should not be used (see section 4.5).</p><p><em>Converting from Banoriv to Vitamin K antagonists (VKA)</em></p><p>There is a potential for inadequate anticoagulation during the transition from Banoriv to VKA. Continuous adequate anticoagulation should be ensured during any transition to an alternate anticoagulant. It should be noted that Banoriv can contribute to an elevated INR.</p><p>In patients converting from Banoriv to VKA, VKA should be given concurrently until the INR is &ge; 2.0. For the first two days of the conversion period, standard initial dosing of VKA should be used followed by VKA dosing, as guided by INR testing. While patients are on both Banoriv and VKA the INR should not be tested earlier than 24 hours after the previous dose but prior to the next dose of Banoriv. Once Banoriv is discontinued INR testing may be done reliably at least 24 hours after the last dose (see sections 4.5 and 5.2).</p><p><em>Converting from parenteral anticoagulants to Banoriv</em></p><p>For patients currently receiving a parenteral anticoagulant, discontinue the parenteral anticoagulant and start Banoriv 0 to 2 hours before the time that the next scheduled administration of the parenteral medicinal product (e.g. low molecular weight heparins) would be due or at the time of discontinuation of a continuously administered parenteral medicinal product (e.g. intravenous unfractionated heparin).</p><p><em>Converting from Banoriv to parenteral anticoagulants</em></p><p>Give the first dose of parenteral anticoagulant at the time the next Banoriv dose would be taken.</p><p><u>Special populations</u></p><p><em>Renal impairment</em></p><p>Limited clinical data for patients with severe renal impairment (creatinine clearance 15 - 29 ml/min) indicate that rivaroxaban plasma concentrations are significantly increased. Therefore, Banoriv is to be used with caution in these patients. Use is not recommended in patients with creatinine clearance &lt; 15 ml/min (see sections 4.4 and 5.2).</p><p>- For the prevention of VTE in adult patients undergoing elective hip or knee replacement surgery, no dose adjustment is necessary in patients with mild renal impairment (creatinine clearance 50 - 80 ml/min) or moderate renal impairment (creatinine clearance 30 - 49 ml/min) (see section 5.2).</p><p>- For the treatment of DVT, treatment of PE and prevention of recurrent DVT and PE, no dose adjustment from the recommended dose is necessary in patients with mild renal impairment (creatinine clearance 50 - 80 ml/min) (see section 5.2).</p><p>In patients with moderate (creatinine clearance 30 - 49 ml/min) or severe (creatinine clearance 15 - 29 ml/min) renal impairment: patients should be treated with 15 mg twice daily for the first 3 weeks. Thereafter, when the recommended dose is 20 mg once daily, a reduction of the dose from 20 mg once daily to 15 mg once daily should be considered if the patient&#39;s assessed risk for bleeding outweighs the risk for recurrent DVT and PE. The recommendation for the use of 15 mg is based on PK modelling and has not been studied in this clinical setting (see sections 4.4, 5.1 and 5.2).</p><p>When the recommended dose is 10 mg once daily, no dose adjustment from the recommended dose is necessary.</p><p><em>Hepatic impairment</em></p><p>Banoriv is contraindicated in patients with hepatic disease associated with coagulopathy and clinically relevant bleeding risk including cirrhotic patients with Child Pugh B and C (see sections 4.3 and 5.2).</p><p><em>Elderly population</em></p><p>No dose adjustment (see section 5.2).</p><p><em>Body weight</em></p><p>No dose adjustment (see section 5.2).</p><p><em>Gender</em></p><p>No dose adjustment (see section 5.2).</p><p><em>Paediatric population</em></p><p>The safety and efficacy of Banoriv in children aged 0 to 18 years have not been established. No data are available. Therefore, Banoriv is not recommended for use in children below 18 years of age.</p><p><u>Method of administration</u></p><p>For oral use.</p><p>Banoriv 10 mg tablets can be taken with or without food (see sections 4.5 and 5.2).</p><p>For patients who are unable to swallow whole tablets, Banoriv tablet may be crushed and mixed with water or apple puree immediately prior to use and administered orally.</p><p>The crushed Banoriv tablet may also be given through gastric tubes after confirmation of the correct gastric placement of the tube. The crushed tablet should be administered in a small amount of water via a gastric tube after which it should be flushed with water (see section 5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Active clinically significant bleeding.
Lesion or condition, if considered to be a significant risk for major bleeding. This may include current or recent gastrointestinal ulceration, presence of malignant neoplasms at high risk of bleeding, recent brain or spinal injury, recent brain, spinal or ophthalmic surgery, recent intracranial haemorrhage, known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities.
Concomitant treatment with any other anticoagulants e.g. unfractionated heparin (UFH), low molecular weight heparins (enoxaparin, dalteparin, etc.), heparin derivatives (fondaparinux, etc.), oral anticoagulants (warfarin, dabigatran etexilate, apixaban, etc.) except under specific circumstances of switching anticoagulant therapy (see section 4.2) or when UFH is given at doses necessary to maintain an open central venous or arterial catheter (see section 4.5).
Hepatic disease associated with coagulopathy and clinically relevant bleeding risk including cirrhotic patients with Child Pugh B and C (see section 5.2).
Pregnancy and breast feeding (see section 4.6).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clinical surveillance in line with anticoagulation practice is recommended throughout the treatment period.</p><p><u>Haemorrhagic risk</u></p><p>As with other anticoagulants, patients taking Banoriv are to be carefully observed for signs of bleeding. It is recommended to be used with caution in conditions with increased risk of haemorrhage. Banoriv administration should be discontinued if severe haemorrhage occurs.</p><p>In the clinical studies mucosal bleedings (i.e. epistaxis, gingival, gastrointestinal, genito urinary including abnormal vaginal or increased menstrual bleeding) and anaemia were seen more frequently during long term rivaroxaban treatment compared with VKA treatment. Thus, in addition to adequate clinical surveillance, laboratory testing of haemoglobin/haematocrit could be of value to detect occult bleeding and quantify the clinical relevance of overt bleeding, as judged to be appropriate.</p><p>Several sub-groups of patients, as detailed below, are at increased risk of bleeding. These patients are to be carefully monitored for signs and symptoms of bleeding complications and anaemia after initiation of treatment (see section 4.8). In patients receiving Banoriv for VTE prevention following elective hip or knee replacement surgery, this may be done by regular physical examination of the patients, close observation of the surgical wound drainage and periodic measurements of haemoglobin.</p><p>Any unexplained fall in haemoglobin or blood pressure should lead to a search for a bleeding site.</p><p>Although treatment with rivaroxaban does not require routine monitoring of exposure, rivaroxaban levels measured with a calibrated quantitative anti-factor Xa assay may be useful in exceptional situations where knowledge of rivaroxaban exposure may help to inform clinical decisions, e.g., overdose and emergency surgery (see sections 5.1 and 5.2).</p><p><u>Renal impairment</u></p><p>In patients with severe renal impairment (creatinine clearance &lt; 30 ml/min) rivaroxaban plasma levels may be significantly increased (1.6-fold on average) which may lead to an increased bleeding risk. Banoriv is to be used with caution in patients with creatinine clearance 15 - 29 ml/min. Use is not recommended in patients with creatinine clearance &lt; 15 ml/min (see sections 4.2 and 5.2).</p><p>In patients with moderate renal impairment (creatinine clearance 30 - 49 ml/min) concomitantly receiving other medicinal products which increase rivaroxaban plasma concentrations Banoriv is to be used with caution (see section 4.5).</p><p><u>Interaction with other medicinal products</u></p><p>The use of Banoriv is not recommended in patients receiving concomitant systemic treatment with azole-antimycotics (such as ketoconazole, itraconazole, voriconazole and posaconazole) or HIV protease inhibitors (e.g. ritonavir). These active substances are strong inhibitors of both CYP3A4 and P-gp and therefore may increase rivaroxaban plasma concentrations to a clinically relevant degree (2.6 fold on average) which may lead to an increased bleeding risk (see section 4.5).</p><p>Care is to be taken if patients are treated concomitantly with medicinal products affecting haemostasis such as non-steroidal anti-inflammatory medicinal products (NSAIDs), acetylsalicylic acid (ASA) and platelet aggregation inhibitors or selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs). For patients at risk of ulcerative gastrointestinal disease an appropriate prophylactic treatment may be considered (see section 4.5).</p><p><u>Other haemorrhagic risk factors</u></p><p>As with other antithrombotics, rivaroxaban is not recommended in patients with an increased bleeding risk such as:</p><p>&bull; congenital or acquired bleeding disorders</p><p>&bull; uncontrolled severe arterial hypertension</p><p>&bull; other gastrointestinal disease&nbsp;<u>without active ulceration</u>&nbsp;that can potentially lead to bleeding complications (e.g. inflammatory bowel disease, oesophagitis, gastritis and gastroesophageal reflux disease)</p><p>&bull; vascular retinopathy</p><p>&bull; bronchiectasis or history of pulmonary bleeding.</p><p><u>Patients with prosthetic valves</u></p><p>Safety and efficacy of Banoriv have not been studied in patients with prosthetic heart valves; therefore, there are no data to support that Banoriv provides adequate anticoagulation in this patient population. Treatment with Banoriv is not recommended for these patients.</p><p><u>Hip fracture surgery</u></p><p>Rivaroxaban has not been studied in interventional clinical trials in patients undergoing hip fracture surgery to evaluate efficacy and safety.</p><p><u>Haemodynamically unstable PE patients or patients who require thrombolysis or pulmonary embolectomy</u></p><p>Banoriv is not recommended as an alternative to unfractionated heparin in patients with pulmonary embolism who are haemodynamically unstable or may receive thrombolysis or pulmonary embolectomy since the safety and efficacy of Banoriv have not been established in these clinical situations.</p><p><u>Spinal/epidural anaesthesia or puncture</u></p><p>When neuraxial anaesthesia (spinal/epidural anaesthesia) or spinal/epidural puncture is employed, patients treated with antithrombotic agents for prevention of thromboembolic complications are at risk of developing an epidural or spinal haematoma which can result in long-term or permanent paralysis. The risk of these events may be increased by the post-operative use of indwelling epidural catheters or the concomitant use of medicinal products affecting haemostasis. The risk may also be increased by traumatic or repeated epidural or spinal puncture. Patients are to be frequently monitored for signs and symptoms of neurological impairment (e.g. numbness or weakness of the legs, bowel or bladder dysfunction). If neurological compromise is noted, urgent diagnosis and treatment is necessary. Prior to neuraxial intervention the physician should consider the potential benefit versus the risk in anticoagulated patients or in patients to be anticoagulated for thromboprophylaxis.</p><p>To reduce the potential risk of bleeding associated with the concurrent use of rivaroxaban and neuraxial (epidural/spinal) anaesthesia or spinal puncture, consider the pharmacokinetic profile of rivaroxaban. Placement or removal of an epidural catheter or lumbar puncture is best performed when the anticoagulant effect of rivaroxaban is estimated to be low (see section 5.2).</p><p>At least 18 hours should elapse after the last administration of rivaroxaban before removal of an epidural catheter. Following removal of the catheter, at least 6 hours should elapse before the next rivaroxaban dose is administered.</p><p>If traumatic puncture occurs the administration of rivaroxaban is to be delayed for 24 hours.</p><p><u>Dosing recommendations before and after invasive procedures and surgical intervention other than elective hip or knee replacement surgery</u></p><p>If an invasive procedure or surgical intervention is required, Banoriv 10 mg should be stopped at least 24 hours before the intervention, if possible and based on the clinical judgement of the physician.</p><p>If the procedure cannot be delayed the increased risk of bleeding should be assessed against the urgency of the intervention.</p><p>Banoriv should be restarted as soon as possible after the invasive procedure or surgical intervention provided the clinical situation allows and adequate haemostasis has been established as determined by the treating physician (see section 5.2).</p><p><u>Elderly population</u></p><p>Increasing age may increase haemorrhagic risk (see section 5.2).</p><p><u>Dermatological reactions</u></p><p>Serious skin reactions, including Stevens-Johnson syndrome/Toxic Epidermal Necrolysis, have been reported during post-marketing surveillance in association with the use of rivaroxaban (see section 4.8). Patients appear to be at highest risk for these reactions early in the course of therapy: the onset of the reaction occurring in the majority of cases within the first weeks of treatment. Rivaroxaban should be discontinued at the first appearance of a severe skin rash (e.g. spreading, intense and/or blistering), or any other sign of hypersensitivity in conjunction with mucosal lesions.</p><p><u>Information about excipients</u></p><p>Banoriv contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>CYP3A4 and P-gp inhibitors</u></p><p>Co-administration of rivaroxaban with ketoconazole (400 mg once a day) or ritonavir (600 mg twice a day) led to a 2.6 fold / 2.5 fold increase in mean rivaroxaban AUC and a 1.7 fold / 1.6 fold increase in mean rivaroxaban C<sub>max</sub>, with significant increases in pharmacodynamic effects which may lead to an increased bleeding risk. Therefore, the use of Banoriv is not recommended in patients receiving concomitant systemic treatment with azole-antimycotics such as ketoconazole, itraconazole, voriconazole and posaconazole or HIV protease inhibitors. These active substances are strong inhibitors of both CYP3A4 and P-gp (see section 4.4).</p><p>Active substances strongly inhibiting only one of the rivaroxaban elimination pathways, either CYP3A4 or P-gp, are expected to increase rivaroxaban plasma concentrations to a lesser extent. Clarithromycin (500 mg twice a day), for instance, considered as a strong CYP3A4 inhibitor and moderate P-gp inhibitor, led to a 1.5 fold increase in mean rivaroxaban AUC and a 1.4 fold increase in C<sub>max</sub>. This increase is not considered clinically relevant. (For patients with renal impairment: see section 4.4).</p><p>Erythromycin (500 mg three times a day), which inhibits CYP3A4 and P-gp moderately, led to a 1.3 fold increase in mean rivaroxaban AUC and C<sub>max</sub>. This increase is not considered clinically relevant.</p><p>In subjects with mild renal impairment erythromycin (500 mg three times a day) led to a 1.8 fold increase in mean rivaroxaban AUC and 1.6 fold increase in C<sub>max</sub>&nbsp;when compared to subjects with normal renal function. In subjects with moderate renal impairment, erythromycin led to a 2.0 fold increase in mean rivaroxaban AUC and 1.6 fold increase in C<sub>max</sub>&nbsp;when compared to subjects with normal renal function. The effect of erythromycin is additive to that of renal impairment (see section 4.4).</p><p>Fluconazole (400 mg once daily), considered as a moderate CYP3A4 inhibitor, led to a 1.4 fold increase in mean rivaroxaban AUC and a 1.3 fold increase in mean C<sub>max</sub>. This increase is not considered clinically relevant. (For patients with renal impairment: see section 4.4).</p><p>Given the limited clinical data available with dronedarone, co-administration with rivaroxaban should be avoided.</p><p><u>Anticoagulants</u></p><p>After combined administration of enoxaparin (40 mg single dose) with rivaroxaban (10 mg single dose) an additive effect on anti-factor Xa activity was observed without any additional effects on clotting tests (PT, aPTT). Enoxaparin did not affect the pharmacokinetics of rivaroxaban.</p><p>Due to the increased bleeding risk care is to be taken if patients are treated concomitantly with any other anticoagulants (see sections 4.3 and 4.4).</p><p><u>NSAIDs/platelet aggregation inhibitors</u></p><p>No clinically relevant prolongation of bleeding time was observed after concomitant administration of rivaroxaban (15 mg) and 500 mg naproxen. Nevertheless, there may be individuals with a more pronounced pharmacodynamic response.</p><p>No clinically significant pharmacokinetic or pharmacodynamic interactions were observed when rivaroxaban was co-administered with 500 mg acetylsalicylic acid.</p><p>Clopidogrel (300 mg loading dose followed by 75 mg maintenance dose) did not show a pharmacokinetic interaction with rivaroxaban (15 mg) but a relevant increase in bleeding time was observed in a subset of patients which was not correlated to platelet aggregation, P-selectin or GPIIb/IIIa receptor levels.</p><p>Care is to be taken if patients are treated concomitantly with NSAIDs (including acetylsalicylic acid) and platelet aggregation inhibitors because these medicinal products typically increase the bleeding risk (see section 4.4).</p><p><u>SSRIs/SNRIs</u></p><p>As with other anticoagulants the possibility may exist that patients are at increased risk of bleeding in case of concomitant use with SSRIs or SNRIs due to their reported effect on platelets. When concomitantly used in the rivaroxaban clinical program, numerically higher rates of major or non-major clinically relevant bleeding were observed in all treatment groups.</p><p><u>Warfarin</u></p><p>Converting patients from the vitamin K antagonist warfarin (INR 2.0 to 3.0) to rivaroxaban (20 mg) or from rivaroxaban (20 mg) to warfarin (INR 2.0 to 3.0) increased prothrombin time/INR (Neoplastin) more than additively (individual INR values up to 12 may be observed), whereas effects on aPTT, inhibition of factor Xa activity and endogenous thrombin potential were additive.</p><p>If it is desired to test the pharmacodynamic effects of rivaroxaban during the conversion period, anti-factor Xa activity, PiCT, and Heptest can be used as these tests were not affected by warfarin. On the fourth day after the last dose of warfarin, all tests (including PT, aPTT, inhibition of factor Xa activity and ETP) reflected only the effect of rivaroxaban.</p><p>If it is desired to test the pharmacodynamic effects of warfarin during the conversion period, INR measurement can be used at the C<sub>trough</sub>&nbsp;of rivaroxaban (24 hours after the previous intake of rivaroxaban) as this test is minimally affected by rivaroxaban at this time point.</p><p>No pharmacokinetic interaction was observed between warfarin and rivaroxaban.</p><p><u>CYP3A4 inducers</u></p><p>Co-administration of rivaroxaban with the strong CYP3A4 inducer rifampicin led to an approximate 50 % decrease in mean rivaroxaban AUC, with parallel decreases in its pharmacodynamic effects. The concomitant use of rivaroxaban with other strong CYP3A4 inducers (e.g. phenytoin, carbamazepine, phenobarbital or St. John&#39;s Wort&nbsp;<em>(Hypericum perforatum)</em>) may also lead to reduced rivaroxaban plasma concentrations. Therefore, concomitant administration of strong CYP3A4 inducers should be avoided unless the patient is closely observed for signs and symptoms of thrombosis.</p><p><u>Other concomitant therapies</u></p><p>No clinically significant pharmacokinetic or pharmacodynamic interactions were observed when rivaroxaban was co-administered with midazolam (substrate of CYP3A4), digoxin (substrate of P-gp), atorvastatin (substrate of CYP3A4 and P-gp) or omeprazole (proton pump inhibitor). Rivaroxaban neither inhibits nor induces any major CYP isoforms like CYP3A4.</p><p>No clinically relevant interaction with food was observed (see section 4.2).</p><p><u>Laboratory parameters</u></p><p>Clotting parameters (e.g. PT, aPTT, HepTest) are affected as expected by the mode of action of rivaroxaban (see section 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>Safety and efficacy of Banoriv have not been established in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). Due to the potential reproductive toxicity, the intrinsic risk of bleeding and the evidence that rivaroxaban passes the placenta, Banoriv is contraindicated during pregnancy (see section 4.3).</p><p>Women of child bearing potential should avoid becoming pregnant during treatment with rivaroxaban.</p><p><u>Breast feeding</u></p><p>Safety and efficacy of Banoriv have not been established in breast feeding women. Data from animals indicate that rivaroxaban is secreted into milk. Therefore Banoriv is contraindicated during breast feeding (see section 4.3). A decision must be made whether to discontinue breast feeding or to discontinue/abstain from therapy.</p><p><u>Fertility</u></p><p>No specific studies with rivaroxaban in humans have been conducted to evaluate effects on fertility. In a study on male and female fertility in rats no effects were seen (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Banoriv has minor influence on the ability to drive and use machines. Adverse reactions like syncope (frequency: uncommon) and dizziness (frequency: common) have been reported (see section 4.8). Patients experiencing these adverse reactions should not drive or use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>The safety of rivaroxaban has been evaluated in twelve phase III studies including 34,859 patients exposed to rivaroxaban (see Table 1).</p><p><strong>Table 1: Number of patients studied, total daily dose and maximum treatment duration in phase III studies</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>Indication</strong></p></td><td style="vertical-align:top"><p><strong>Number of patients*</strong></p></td><td style="vertical-align:top"><p><strong>Total daily dose</strong></p></td><td style="vertical-align:top"><p><strong>Maximum treatment duration</strong></p></td></tr><tr><td style="vertical-align:top"><p>Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery</p></td><td style="vertical-align:top"><p>6,097</p></td><td style="vertical-align:top"><p>10 mg</p></td><td style="vertical-align:top"><p>39 days</p></td></tr><tr><td style="vertical-align:top"><p>Prevention of venous thromboembolism in medically ill patients</p></td><td style="vertical-align:top"><p>3,997</p></td><td style="vertical-align:top"><p>10 mg</p></td><td style="vertical-align:top"><p>39 days</p></td></tr><tr><td style="vertical-align:top"><p>Treatment of DVT, PE and prevention of recurrence</p></td><td style="vertical-align:top"><p>6,790</p></td><td style="vertical-align:top"><p>Day 1 - 21: 30 mg</p><p>Day 22 and onwards: 20 mg</p><p>After at least 6 months: 10 mg or 20 mg</p></td><td style="vertical-align:top"><p>21 months</p></td></tr><tr><td style="vertical-align:top"><p>Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation</p></td><td style="vertical-align:top"><p>7,750</p></td><td style="vertical-align:top"><p>20 mg</p></td><td style="vertical-align:top"><p>41 months</p></td></tr><tr><td style="vertical-align:top"><p>Prevention of atherothrombotic events in patients after an ACS</p></td><td style="vertical-align:top"><p>10,225</p></td><td style="vertical-align:top"><p>5 mg or 10 mg respectively, co-administered with either ASA or ASA plus clopidogrel or ticlopidine</p></td><td style="vertical-align:top"><p>31 months</p></td></tr></tbody></table><p>*Patients exposed to at least one dose of rivaroxaban</p><p>The most commonly reported adverse reactions in patients receiving rivaroxaban were bleedings (see section 4.4. and &#39;Description of selected adverse reactions&#39; below) (Table 2). The most commonly reported bleedings (&ge;4 %) were epistaxis (5.8 %) and gastrointestinal tract haemorrhage (4.1 %).</p><p>In total about 65% of patients exposed to at least one dose of rivaroxaban were reported with treatment emergent adverse events. About 21% of the patients experienced adverse events considered related to treatment as assessed by investigators.</p><p><strong>Table 2 Bleeding and anaemia events rates in patients exposed to rivaroxaban across the completed phase III studies:</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>Indication</strong></p></td><td style="vertical-align:top"><p><strong>Any Bleeding</strong></p></td><td style="vertical-align:top"><p><strong>Anaemia</strong></p></td></tr><tr><td style="vertical-align:top"><p>Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery</p></td><td style="vertical-align:top"><p>6.8% of patients</p></td><td style="vertical-align:top"><p>5.9% of patients</p></td></tr><tr><td style="vertical-align:top"><p>Prevention of venous thromboembolism in medically ill patients</p></td><td style="vertical-align:top"><p>12.6% of patients</p></td><td style="vertical-align:top"><p>2.1% of patients</p></td></tr><tr><td style="vertical-align:top"><p>Treatment of DVT, PE and prevention of recurrence</p></td><td style="vertical-align:top"><p>23% of patients</p></td><td style="vertical-align:top"><p>1.6% of patients</p></td></tr><tr><td style="vertical-align:top"><p>Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation</p></td><td style="vertical-align:top"><p>28 per 100 patient years</p></td><td style="vertical-align:top"><p>2.5 per 100 patient years</p></td></tr><tr><td style="vertical-align:top"><p>Prevention of atherothrombotic events in patients after an ACS</p></td><td style="vertical-align:top"><p>22 per 100 patient years</p></td><td style="vertical-align:top"><p>1.4 per 100 patient years</p></td></tr></tbody></table><p><u>Tabulated list of adverse reactions</u></p><p>The frequencies of adverse reactions reported with Banoriv are summarised in table 3 below by system organ class (in MedDRA) and by frequency.</p><p>Frequencies are defined as:</p><p>very common (&ge; 1/10)</p><p>common (&ge; 1/100 to &lt; 1/10)</p><p>uncommon (&ge; 1/1,000 to &lt; 1/100)</p><p>rare (&ge; 1/10,000 to &lt; 1/1,000)</p><p>very rare (&lt; 1/10,000)</p><p>not known (cannot be estimated from the available data)</p><p><strong>Table 3: All treatment-emergent adverse reactions reported in patients in phase III studies</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td><p><strong>Common</strong></p></td><td><p><strong>Uncommon</strong></p></td><td><p><strong>Rare</strong></p></td><td><p><strong>Not known</strong></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Anaemia (incl. respective laboratory parameters)</p></td><td style="vertical-align:top"><p>Thrombocytosis (incl. platelet count increased)<sup>A</sup></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Allergic reaction, dermatitis allergic</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Dizziness, headache</p></td><td style="vertical-align:top"><p>Cerebral and intracranial haemorrhage, syncope</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Eye disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Eye haemorrhage (incl. conjunctival haemorrhage)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Tachycardia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Hypotension, haematoma</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Epistaxis, haemoptysis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Gingival bleeding, gastrointestinal tract haemorrhage (incl. rectal haemorrhage), gastrointestinal and abdominal pains, dyspepsia, nausea, constipation<sup>A</sup>, diarrhoea, vomiting<sup>A</sup></p></td><td style="vertical-align:top"><p>Dry mouth</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Hepatic impairment</p></td><td style="vertical-align:top"><p>Jaundice</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Pruritus (incl. uncommon cases of generalised pruritus), rash, ecchymosis, cutaneous and subcutaneous haemorrhage</p></td><td style="vertical-align:top"><p>Urticaria</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Pain in extremity<sup>A</sup></p></td><td style="vertical-align:top"><p>Haemarthrosis</p></td><td style="vertical-align:top"><p>Muscle haemorrhage</p></td><td style="vertical-align:top"><p>Compartment syndrome secondary to a bleeding</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Urogenital tract haemorrhage (incl. haematuria and menorrhagia<sup>B</sup>), renal impairment (incl. blood creatinine increased, blood urea increased)<sup>A</sup></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Renal failure/acute renal failure secondary to a bleeding sufficient to cause hypoperfusion</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Fever<sup>A</sup>, peripheral oedema, decreased general strength and energy (incl. fatigue and asthenia)</p></td><td style="vertical-align:top"><p>Feeling unwell (incl. malaise)</p></td><td style="vertical-align:top"><p>Localised oedema<sup>A</sup></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Investigations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Increase in transaminases</p></td><td style="vertical-align:top"><p>Increased bilirubin, increased blood alkaline phosphatase<sup>A</sup>, increased LDH<sup>A</sup>, increased lipase<sup>A</sup>, increased amylase<sup>A</sup>, increased GGT<sup>A</sup></p></td><td style="vertical-align:top"><p>Bilirubin conjugated increased (with or without concomitant increase of ALT)</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Injury, poisoning and procedural complications</strong></p></td></tr><tr><td style="vertical-align:top"><p>Postprocedural haemorrhage (incl. postoperative anaemia, and wound haemorrhage), contusion, wound secretion<sup>A</sup></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Vascular pseudoaneurysm<sup>C</sup></p></td><td style="vertical-align:top">&nbsp;</td></tr></tbody></table><p>A: observed in prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery</p><p>B: observed in treatment of DVT, PE and prevention of recurrence as very common in women &lt; 55 years</p><p>C: observed as uncommon in prevention of atherothrombotic events in patients after an ACS (following percutaneous coronary intervention)</p><p><u>Description of selected adverse reactions</u></p><p>Due to the pharmacological mode of action, the use of Banoriv may be associated with an increased risk of occult or overt bleeding from any tissue or organ which may result in post haemorrhagic anaemia. The signs, symptoms, and severity (including fatal outcome) will vary according to the location and degree or extent of the bleeding and/or anaemia (see section 4.9 Management of bleeding). In the clinical studies mucosal bleedings (i.e. epistaxis, gingival, gastrointestinal, genito urinary including abnormal vaginal or increased menstrual bleeding) and anaemia were seen more frequently during long term rivaroxaban treatment compared with VKA treatment. Thus, in addition to adequate clinical surveillance, laboratory testing of haemoglobin/haematocrit could be of value to detect occult bleeding and quantify the clinical relevance of overt bleeding, as judged to be appropriate. The risk of bleedings may be increased in certain patient groups e.g. those patients with uncontrolled severe arterial hypertension and/or on concomitant treatment affecting haemostasis (see Haemorrhagic risk in section 4.4). Menstrual bleeding may be intensified and/or prolonged. Haemorrhagic complications may present as weakness, paleness, dizziness, headache or unexplained swelling, dyspnoea and unexplained shock. In some cases as a consequence of anaemia, symptoms of cardiac ischaemia like chest pain or angina pectoris have been observed.</p><p>Known complications secondary to severe bleeding such as compartment syndrome and renal failure due to hypoperfusion have been reported for Banoriv. Therefore, the possibility of haemorrhage is to be considered in evaluating the condition in any anticoagulated patient.</p><p><u>Post-marketing observations</u></p><p>The following adverse reactions have been reported post-marketing in temporal association with the use of Banoriv. The frequency of these adverse reactions reported from post-marketing experience cannot be estimated.</p><p>Immune system disorders: Angioedema and allergic oedema (In the pooled phase III trials, these events were uncommon (&ge; 1/1,000 to &lt; 1/100)).</p><p>Hepatobiliary disorders: Cholestasis, Hepatitis (incl. hepatocellular injury) (In the pooled phase III trials, these events were rare (&ge; 1/10,000 to &lt; 1/1,000)).</p><p>Blood and lymphatic system disorders: Thrombocytopenia (In the pooled phase III trials, these events were uncommon (&ge; 1/1,000 to &lt; 1/100)).</p><p>Skin and subcutaneous tissue disorders: Stevens-Johnson syndrome/Toxic Epidermal Necrolysis (In the pooled phase III trials, these events were estimated as very rare (&lt;1/10,000)).</p><p><u>Reporting of suspected adverse reactions</u></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>To report any side effect(s):</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>Fax: +966-11-205-7662</p><p>Call NPC at:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; +966-11-2038222&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Exts: 2317-2356-2353-2354-2334-2340.</p><p>Toll free phone: 8002490000</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: www.sfda.gov.sa/npc</p><p>&nbsp;</p></td></tr></tbody></table></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Rare cases of overdose up to 600 mg have been reported without bleeding complications or other adverse reactions. Due to limited absorption a ceiling effect with no further</p><p>increase in average plasma exposure is expected at supratherapeutic doses of 50 mg rivaroxaban or above.</p><p>A specific antidote antagonising the pharmacodynamic effect of rivaroxaban is not available.</p><p>The use of activated charcoal to reduce absorption in case of rivaroxaban overdose may be considered.</p><p><u>Management of bleeding</u></p><p>Should a bleeding complication arise in a patient receiving rivaroxaban, the next rivaroxaban administration should be delayed or treatment should be discontinued as appropriate. Rivaroxaban has a half-life of approximately 5 to 13 hours (see section 5.2). Management should be individualised according to the severity and location of the haemorrhage. Appropriate symptomatic treatment could be used as needed, such as mechanical compression (e.g. for severe epistaxis), surgical haemostasis with bleeding control procedures, fluid replacement and haemodynamic support, blood products (packed red cells or fresh frozen plasma, depending on associated anaemia or coagulopathy) or platelets.</p><p>If bleeding cannot be controlled by the above measures, administration of a specific procoagulant reversal agent should be considered, such as prothrombin complex concentrate (PCC), activated prothrombin complex concentrate (APCC) or recombinant factor VIIa (r-FVIIa). However, there is currently very limited clinical experience with the use of these products in individuals receiving rivaroxaban. The recommendation is also based on limited non-clinical data. Re-dosing of recombinant factor VIIa shall be considered and titrated depending on improvement of bleeding. Depending on local availability, a consultation with a coagulation expert should be considered in case of major bleedings (see section 5.1).</p><p>Protamine sulfate and vitamin K are not expected to affect the anticoagulant activity of rivaroxaban. There is limited experience with tranexamic acid and no experience with aminocaproic acid and aprotinin in individuals receiving rivaroxaban. There is neither scientific rationale for benefit nor experience with the use of the systemic haemostatic desmopressin in individuals receiving rivaroxaban. Due to the high plasma protein binding rivaroxaban is not expected to be dialysable.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Direct factor Xa inhibitors, ATC code: B01AF01</p><p><u>Mechanism of action</u></p><p>Rivaroxaban is a highly selective direct factor Xa inhibitor with oral bioavailability. Inhibition of factor Xa interrupts the intrinsic and extrinsic pathway of the blood coagulation cascade, inhibiting both thrombin formation and development of thrombi. Rivaroxaban does not inhibit thrombin (activated factor II) and no effects on platelets have been demonstrated.</p><p><u>Pharmacodynamic effects</u></p><p>Dose-dependent inhibition of factor Xa activity was observed in humans. Prothrombin time (PT) is influenced by rivaroxaban in a dose dependent way with a close correlation to plasma concentrations (r value equals 0.98) if Neoplastin is used for the assay. Other reagents would provide different results. The readout for PT is to be done in seconds, because the INR (International Normalised Ratio) is only calibrated and validated for coumarins and cannot be used for any other anticoagulant. In patients undergoing major orthopaedic surgery, the 5/95 percentiles for PT (Neoplastin) 2 - 4 hours after tablet intake (i.e. at the time of maximum effect) ranged from 13 to 25 s (baseline values before surgery 12 to 15s).</p><p>In a clinical pharmacology study on the reversal of rivaroxaban pharmacodynamics in healthy adult subjects (n=22), the effects of single doses (50 IU/kg) of two different types of PCCs, a 3-factor PCC (Factors II, IX and X) and a 4-factor PCC (Factors II, VII, IX and X) were assessed. The 3-factor PCC reduced mean Neoplastin PT values by approximately 1.0 second within 30 minutes, compared to reductions of approximately 3.5 seconds observed with the 4-factor PCC. In contrast, the 3-factor PCC had a greater and more rapid overall effect on reversing changes in endogenous thrombin generation than the 4-factor PCC (see section 4.9).</p><p>The activated partial thomboplastin time (aPTT) and HepTest are also prolonged dose-dependently; however, they are not recommended to assess the pharmacodynamic effect of rivaroxaban.</p><p>There is no need for monitoring of coagulation parameters during treatment with rivaroxaban in clinical routine. However, if clinically indicated rivaroxaban levels can be measured by calibrated quantitative anti-factor Xa tests (see section 5.2).</p><p><u>Clinical efficacy and safety</u></p><p><em>Prevention of VTE in adult patients undergoing elective hip or knee replacement surgery</em></p><p>The rivaroxaban clinical programme was designed to demonstrate the efficacy of rivaroxaban for the prevention of VTE, i.e. proximal and distal deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients undergoing major orthopaedic surgery of the lower limbs. Over 9,500 patients (7,050 in total hip replacement surgery and 2,531 in total knee replacement surgery) were studied in controlled randomised double-blind phase III clinical studies, the RECORD-programme.</p><p>Rivaroxaban 10 mg once daily (od) started no sooner than 6 hours post-operatively was compared with enoxaparin 40 mg once daily started 12 hours pre-operatively.</p><p>In all three phase III studies (see table 4), rivaroxaban significantly reduced the rate of total VTE (any venographically detected or symptomatic DVT, non-fatal PE and death) and major VTE (proximal DVT, non-fatal PE and VTE-related death), the pre-specified primary and major secondary efficacy endpoints. Furthermore, in all three studies the rate of symptomatic VTE (symptomatic DVT, non-fatal PE, VTE-related death) was lower in rivaroxaban treated patients compared to patients treated with enoxaparin.</p><p>The main safety endpoint, major bleeding, showed comparable rates for patients treated with rivaroxaban 10 mg compared to enoxaparin 40 mg.</p><p><strong>Table 4: Efficacy and safety results from phase III clinical studies</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top">&nbsp;</td><td colspan="3" style="vertical-align:top"><p>RECORD 1</p></td><td colspan="3" style="vertical-align:top"><p>RECORD 2</p></td><td colspan="3" style="vertical-align:top"><p>RECORD 3</p></td></tr><tr><td style="vertical-align:top"><p>Study Population</p></td><td colspan="3" style="vertical-align:top"><p>4,541 patients undergoing total hip replacement surgery</p></td><td colspan="3" style="vertical-align:top"><p>2,509 patients undergoing total hip replacement surgery</p></td><td colspan="3" style="vertical-align:top"><p>2,531 patients undergoing total knee replacement surgery</p></td></tr><tr><td style="vertical-align:top"><p>Treatment dose and duration after surgery</p></td><td style="vertical-align:top"><p>Rivaroxaban</p><p>10 mg od</p><p>35 &plusmn; 4 days</p></td><td style="vertical-align:top"><p>Enoxaparin</p><p>40 mg od</p><p>35 &plusmn; 4 days</p></td><td style="vertical-align:top"><p>p</p></td><td style="vertical-align:top"><p>Rivaroxaban</p><p>10 mg od</p><p>35 &plusmn; 4 days</p></td><td style="vertical-align:top"><p>Enoxaparin</p><p>40 mg od</p><p>12 &plusmn; 2 days</p></td><td style="vertical-align:top"><p>p</p></td><td style="vertical-align:top"><p>Rivaroxaban</p><p>10 mg od</p><p>12 &plusmn; 2 days</p></td><td style="vertical-align:top"><p>Enoxaparin</p><p>40 mg od</p><p>12 &plusmn; 2 days</p></td><td style="vertical-align:top"><p>p</p></td></tr><tr><td style="vertical-align:top"><p>Total VTE</p></td><td style="vertical-align:top"><p>18 (1.1 %)</p></td><td style="vertical-align:top"><p>58 (3.7 %)</p></td><td style="vertical-align:top"><p>&lt; 0.001</p></td><td style="vertical-align:top"><p>17 (2.0 %)</p></td><td style="vertical-align:top"><p>81 (9.3 %)</p></td><td style="vertical-align:top"><p>&lt; 0.001</p></td><td style="vertical-align:top"><p>79 (9.6 %)</p></td><td style="vertical-align:top"><p>166 (18.9 %)</p></td><td style="vertical-align:top"><p>&lt; 0.001</p></td></tr><tr><td style="vertical-align:top"><p>Major VTE</p></td><td style="vertical-align:top"><p>4 (0.2 %)</p></td><td style="vertical-align:top"><p>33 (2.0 %)</p></td><td style="vertical-align:top"><p>&lt; 0.001</p></td><td style="vertical-align:top"><p>6 (0.6 %)</p></td><td style="vertical-align:top"><p>49 (5.1 %)</p></td><td style="vertical-align:top"><p>&lt; 0.001</p></td><td style="vertical-align:top"><p>9 (1.0 %)</p></td><td style="vertical-align:top"><p>24 (2.6 %)</p></td><td style="vertical-align:top"><p>0.01</p></td></tr><tr><td style="vertical-align:top"><p>Symptomatic VTE</p></td><td style="vertical-align:top"><p>6 (0.4 %)</p></td><td style="vertical-align:top"><p>11 (0.7 %)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>3 (0.4 %)</p></td><td style="vertical-align:top"><p>15 (1.7 %)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>8 (1.0 %)</p></td><td style="vertical-align:top"><p>24 (2.7 %)</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Major bleedings</p></td><td style="vertical-align:top"><p>6 (0.3 %)</p></td><td style="vertical-align:top"><p>2 (0.1 %)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>1 (0.1 %)</p></td><td style="vertical-align:top"><p>1 (0.1 %)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>7 (0.6 %)</p></td><td style="vertical-align:top"><p>6 (0.5 %)</p></td><td style="vertical-align:top">&nbsp;</td></tr></tbody></table><p>The analysis of the pooled results of the phase III trials corroborated the data obtained in the individual studies regarding reduction of total VTE, major VTE and symptomatic VTE with rivaroxaban 10 mg once daily compared to enoxaparin 40 mg once daily.</p><p>In addition to the phase III RECORD program, a post-authorization, non-interventional, open-label cohort study (XAMOS) has been conducted in 17,413 patients undergoing major orthopaedic surgery of the hip or knee, to compare rivaroxaban with other pharmacological thromboprophylaxis (standard-of-care) under real-life setting. Symptomatic VTE occurred in 57 (0.6%) patients in the rivaroxaban group (n=8,778) and 88 (1.0%) of patients in the standard-of-care group (n=8,635; HR 0.63; 95% CI 0.43-0.91); safety population). Major bleeding occurred in 35 (0.4%) and 29 (0.3%) of patients in the rivaroxaban and standard-of-care groups (HR 1.10; 95% CI 0.67-1.80). Thus, the results were consistent with the results of the pivotal randomised studies.</p><p><em>Treatment of DVT, PE and prevention of recurrent DVT and PE</em></p><p>The Banoriv clinical program was designed to demonstrate the efficacy of Banoriv in the initial and continued treatment of acute DVT and PE and prevention of recurrence.</p><p>Over 12,800 patients were studied in four randomised controlled phase III clinical studies (Einstein DVT, Einstein PE, Einstein Extension and Einstein Choice). and additionally a predefined pooled analysis of the Einstein DVT and Einstein PE studies was conducted. The overall combined treatment duration in all studies was up to 21 months.</p><p>In Einstein DVT 3,449 patients with acute DVT were studied for the treatment of DVT and the prevention of recurrent DVT and PE (patients who presented with symptomatic PE were excluded from this study). The treatment duration was for 3, 6 or 12 months depending on the clinical judgement of the investigator.</p><p>For the initial 3 week treatment of acute DVT 15 mg rivaroxaban was administered twice daily. This was followed by 20 mg rivaroxaban once daily.</p><p>In Einstein PE, 4,832 patients with acute PE were studied for the treatment of PE and the prevention of recurrent DVT and PE. The treatment duration was for 3, 6 or 12 months depending on the clinical judgement of the investigator.</p><p>For the initial treatment of acute PE 15 mg rivaroxaban was administered twice daily for three weeks. This was followed by 20 mg rivaroxaban once daily.</p><p>In both the Einstein DVT and the Einstein PE study, the comparator treatment regimen consisted of enoxaparin administered for at least 5 days in combination with vitamin K antagonist treatment until the PT/INR was in therapeutic range (&ge; 2.0). Treatment was continued with a vitamin K antagonist dose-adjusted to maintain the PT/INR values within the therapeutic range of 2.0 to 3.0.</p><p>In Einstein Extension 1,197 patients with DVT or PE were studied for the prevention of recurrent DVT and PE. The treatment duration was for an additional 6 or 12 months in patients who had completed 6 to 12 months of treatment for venous thromboembolism depending on the clinical judgment of the investigator. Banoriv 20 mg once daily was compared with placebo.</p><p>Einstein DVT, PE and Extension used the same pre-defined primary and secondary efficacy outcomes. The primary efficacy outcome was symptomatic recurrent VTE defined as the composite of recurrent DVT or fatal or non-fatal PE. The secondary efficacy outcome was defined as the composite of recurrent DVT, non-fatal PE and all cause mortality.</p><p>In Einstein Choice, 3,396 patients with confirmed symptomatic DVT and/or PE who completed 6-12 months of anticoagulant treatment were studied for the prevention of fatal PE or non-fatal symptomatic recurrent DVT or PE. Patients with an indication for continued therapeutic-dosed anticoagulation were excluded from the study. The treatment duration was up to 12 months depending on the individual randomization date (median : 351 days). Banoriv 20 mg once daily and Banoriv 10 mg once daily were compared with 100 mg acetylsalicylic acid once daily.</p><p>The primary efficacy outcome was symptomatic recurrent VTE defined as the composite of recurrent DVT or fatal or non-fatal PE.</p><p>In the Einstein DVT study (see Table 5) rivaroxaban was demonstrated to be non-inferior to enoxaparin/VKA for the primary efficacy outcome (p &lt; 0.0001 (test for non-inferiority); hazard ratio: 0.680 (0.443 - 1.042), p=0.076 (test for superiority)). The prespecified net clinical benefit (primary efficacy outcome plus major bleeding events) was reported with a hazard ratio of 0.67 ((95% CI: 0.47 - 0.95), nominal p value p=0.027) in favour of rivaroxaban. INR values were within the therapeutic range a mean of 60.3% of the time for the mean treatment duration of 189 days, and 55.4%, 60.1%, and 62.8% of the time in the 3-, 6-, and 12-month intended treatment duration groups, respectively. In the enoxaparin/VKA group, there was no clear relation between the level of mean centre TTR (Time in Target INR Range of 2.0 &ndash; 3.0) in the equally sized tertiles and the incidence of the recurrent VTE (P=0.932 for interaction). Within the highest tertile according to centre, the hazard ratio with rivaroxaban versus warfarin was 0.69 (95% CI: 0.35 - 1.35).</p><p>The incidence rates for the primary safety outcome (major or clinically relevant non-major bleeding events) as well as the secondary safety outcome (major bleeding events) were similar for both treatment groups.</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Table 5: Efficacy and safety results from phase III Einstein DVT</strong></p></td></tr><tr><td><p>Study population</p></td><td colspan="2"><p>3,449 patients with symptomatic acute deep vein thrombosis</p></td></tr><tr><td><p>Treatment dosage and duration</p></td><td><p>Banoriv<sup>a)</sup></p><p>3, 6 or 12 months</p><p>N=1,731</p></td><td><p>Enoxaparin/VKA<sup>b)</sup></p><p>3, 6 or 12 months</p><p>N=1,718</p></td></tr><tr><td><p>Symptomatic recurrent VTE*</p></td><td><p>36</p><p>(2.1%)</p></td><td><p>51</p><p>(3.0%)</p></td></tr><tr><td><p>Symptomatic recurrent PE</p></td><td><p>20</p><p>(1.2%)</p></td><td><p>18</p><p>(1.0%)</p></td></tr><tr><td><p>Symptomatic recurrent DVT</p></td><td><p>14</p><p>(0.8%)</p></td><td><p>28</p><p>(1.6%)</p></td></tr><tr><td><p>Symptomatic PE and DVT</p></td><td><p>1</p><p>(0.1%)</p></td><td><p>0</p></td></tr><tr><td><p>Fatal PE/Death where PE cannot be ruled out</p></td><td><p>4</p><p>(0.2%)</p></td><td><p>6</p><p>(0.3%)</p></td></tr><tr><td><p>Major or clinically relevant non-major bleeding</p></td><td><p>139</p><p>(8.1%)</p></td><td><p>138</p><p>(8.1%)</p></td></tr><tr><td><p>Major bleeding events</p></td><td><p>14</p><p>(0.8%)</p></td><td><p>20</p><p>(1.2%)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>a) Rivaroxaban 15 mg twice daily for 3 weeks followed by 20 mg once daily</p><p>b) Enoxaparin for at least 5 days, overlapped with and followed by VKA</p><p><strong>*</strong>&nbsp;p &lt; 0.0001 (non-inferiority to a prespecified hazard ratio of 2.0); hazard ratio: 0.680 (0.443 - 1.042), p=0.076 (superiority)</p></td></tr></tbody></table><p>In the Einstein PE study (see Table 6) rivaroxaban was demonstrated to be non-inferior to enoxaparin/VKA for the primary efficacy outcome (p=0.0026 (test for non-inferiority); hazard ratio: 1.123 (0.749 &ndash; 1.684)). The prespecified net clinical benefit (primary efficacy outcome plus major bleeding events) was reported with a hazard ratio of 0.849 ((95% CI: 0.633 - 1.139), nominal p value p= 0.275). INR values were within the therapeutic range a mean of 63% of the time for the mean treatment duration of 215 days, and 57%, 62%, and 65% of the time in the 3-, 6-, and 12-month intended treatment duration groups, respectively. In the enoxaparin/VKA group, there was no clear relation between the level of mean centre TTR (Time in Target INR Range of 2.0 &ndash; 3.0) in the equally sized tertiles and the incidence of the recurrent VTE (p=0.082 for interaction). Within the highest tertile according to centre, the hazard ratio with rivaroxaban versus warfarin was 0.642 (95% CI: 0.277 - 1.484).</p><p>The incidence rates for the primary safety outcome (major or clinically relevant non-major bleeding events) were slightly lower in the rivaroxaban treatment group (10.3% (249/2412)) than in the enoxaparin/VKA treatment group (11.4% (274/2405)). The incidence of the secondary safety outcome (major bleeding events) was lower in the rivaroxaban group (1.1% (26/2412)) than in the enoxaparin/VKA group (2.2% (52/2405)) with a hazard ratio 0.493 (95% CI: 0.308 - 0.789).</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Table 6: Efficacy and safety results from phase III Einstein PE</strong></p></td></tr><tr><td><p>Study population</p></td><td colspan="2"><p>4,832 patients with an acute symptomatic PE</p></td></tr><tr><td><p>Treatment dosage and duration</p></td><td><p>Banoriv<sup>a)</sup></p><p>3, 6 or 12 months</p><p>N=2,419</p></td><td><p>Enoxaparin/VKA<sup>b)</sup></p><p>3, 6 or 12 months</p><p>N=2,413</p></td></tr><tr><td><p>Symptomatic recurrent VTE*</p></td><td><p>50</p><p>(2.1%)</p></td><td><p>44</p><p>(1.8%)</p></td></tr><tr><td><p>Symptomatic recurrent PE</p></td><td><p>23</p><p>(1.0%)</p></td><td><p>20</p><p>(0.8%)</p></td></tr><tr><td><p>Symptomatic recurrent DVT</p></td><td><p>18</p><p>(0.7%)</p></td><td><p>17</p><p>(0.7%)</p></td></tr><tr><td><p>Symptomatic PE and DVT</p></td><td><p>0</p></td><td><p>2</p><p>(&lt;0.1%)</p></td></tr><tr><td><p>Fatal PE/Death where PE cannot be ruled out</p></td><td><p>11</p><p>(0.5%)</p></td><td><p>7</p><p>(0.3%)</p></td></tr><tr><td><p>Major or clinically relevant non-major bleeding</p></td><td><p>249</p><p>(10.3%)</p></td><td><p>274</p><p>(11.4%)</p></td></tr><tr><td><p>Major bleeding events</p></td><td><p>26</p><p>(1.1%)</p></td><td><p>52</p><p>(2.2%)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>a) Rivaroxaban 15 mg twice daily for 3 weeks followed by 20 mg once daily</p><p>b) Enoxaparin for at least 5 days, overlapped with and followed by VKA</p><p>* p &lt; 0.0026 (non-inferiority to a prespecified hazard ratio of 2.0); hazard ratio: 1.123 (0.749 &ndash; 1.684)</p></td></tr></tbody></table><p>A prespecified pooled analysis of the outcome of the Einstein DVT and PE studies was conducted (see Table 7).</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Table 7: Efficacy and safety results from pooled analysis of phase III Einstein DVT and Einstein PE</strong></p></td></tr><tr><td><p>Study population</p></td><td colspan="2"><p>8,281 patients with an acute symptomatic DVT or PE</p></td></tr><tr><td><p>Treatment dosage and duration</p></td><td><p>Banoriv<sup>a)</sup></p><p>3, 6 or 12 months</p><p>N=4,150</p></td><td><p>Enoxaparin/VKA<sup>b)</sup></p><p>3, 6 or 12 months</p><p>N=4,131</p></td></tr><tr><td><p>Symptomatic recurrent VTE*</p></td><td><p>86</p><p>(2.1%)</p></td><td><p>95</p><p>(2.3%)</p></td></tr><tr><td><p>Symptomatic recurrent PE</p></td><td><p>43</p><p>(1.0%)</p></td><td><p>38</p><p>(0.9%)</p></td></tr><tr><td><p>Symptomatic recurrent DVT</p></td><td><p>32</p><p>(0.8%)</p></td><td><p>45</p><p>(1.1%)</p></td></tr><tr><td><p>Symptomatic PE and DVT</p></td><td><p>1</p><p>(&lt;0.1%)</p></td><td><p>2</p><p>(&lt;0.1%)</p></td></tr><tr><td><p>Fatal PE/Death where PE cannot be ruled out</p></td><td><p>15</p><p>(0.4%)</p></td><td><p>13</p><p>(0.3%)</p></td></tr><tr><td><p>Major or clinically relevant non-major bleeding</p></td><td><p>388</p><p>(9.4%)</p></td><td><p>412</p><p>(10.0%)</p></td></tr><tr><td><p>Major bleeding events</p></td><td><p>40</p><p>(1.0%)</p></td><td><p>72</p><p>(1.7%)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>a) Rivaroxaban 15 mg twice daily for 3 weeks followed by 20 mg once daily</p><p>b) Enoxaparin for at least 5 days, overlapped with and followed by VKA</p><p><strong>*</strong>&nbsp;p &lt; 0.0001 (non-inferiority to a prespecified hazard ratio of 1.75); hazard ratio: 0.886 (0.661 &ndash; 1.186)</p></td></tr></tbody></table><p>The prespecified net clinical benefit (primary efficacy outcome plus major bleeding events) of the pooled analysis was reported with a hazard ratio of 0.771 ((95% CI: 0.614 &ndash; 0.967), nominal p value p= 0.0244).</p><p>In the Einstein Extension study (see Table 8) rivaroxaban was superior to placebo for the primary and secondary efficacy outcomes. For the primary safety outcome (major bleeding events) there was a non-significant numerically higher incidence rate for patients treated with rivaroxaban 20 mg once daily compared to placebo. The secondary safety outcome (major or clinically relevant non-major bleeding events) showed higher rates for patients treated with rivaroxaban 20 mg once daily compared to placebo.</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Table 8: Efficacy and safety results from phase III Einstein Extension</strong></p></td></tr><tr><td><p>Study population</p></td><td colspan="2"><p>1,197 patients continued treatment and prevention of recurrent venous thromboembolism</p></td></tr><tr><td><p>Treatment dosage and duration</p></td><td><p>Banoriv<sup>a)</sup></p><p>6 or 12 months</p><p>N=602</p></td><td><p>Placebo</p><p>6 or 12 months</p><p>N=594</p></td></tr><tr><td><p>Symptomatic recurrent VTE*</p></td><td><p>8</p><p>(1.3%)</p></td><td><p>42</p><p>(7.1%)</p></td></tr><tr><td><p>Symptomatic recurrent PE</p></td><td><p>2</p><p>(0.3%)</p></td><td><p>13</p><p>(2.2%)</p></td></tr><tr><td><p>Symptomatic recurrent DVT</p></td><td><p>5</p><p>(0.8%)</p></td><td><p>31</p><p>(5.2%)</p></td></tr><tr><td><p>Fatal PE/Death where PE cannot be ruled out</p></td><td><p>1</p><p>(0.2%)</p></td><td><p>1</p><p>(0.2%)</p></td></tr><tr><td><p>Major bleeding events</p></td><td><p>4</p><p>(0.7%)</p></td><td><p>0</p><p>(0.0%)</p></td></tr><tr><td><p>Clinically relevant non-major bleeding</p></td><td><p>32</p><p>(5.4%)</p></td><td><p>7</p><p>(1.2%)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>a) Rivaroxaban 20 mg once daily</p><p><strong>*</strong>&nbsp;p &lt; 0.0001 (superiority), hazard ratio: 0.185 (0.087 - 0.393)</p></td></tr></tbody></table><p>In the Einstein Choice study (Table 9) Banoriv 20 mg and 10 mg were both superior to 100 mg acetylsalicylic acid for the primary efficacy outcome. The principal safety outcome (major bleeding events) was similar for patients treated with Banoriv 20 mg and 10 mg once daily compared to 100 mg acetylsalicylic acid.</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td colspan="4" style="vertical-align:top"><p><strong>Table 9: Efficacy and safety results from phase III Einstein Choice</strong></p></td></tr><tr><td><p>Study population</p></td><td colspan="3" style="vertical-align:top"><p>3,396 patients continued prevention of recurrent venous thromboembolism</p></td></tr><tr><td><p>Treatment dosage</p></td><td><p>Banoriv 20 mg od</p><p>N=1,107</p></td><td><p>Banoriv 10 mg od</p><p>N=1,127</p></td><td><p>ASA 100 mg od</p><p>N=1,131</p></td></tr><tr><td><p>Treatment duration median [interquartile range]</p></td><td><p>349 [189-362] days</p></td><td><p>353 [190-362] days</p></td><td><p>350 [186-362] days</p></td></tr><tr><td><p>Symptomatic recurrent VTE</p></td><td><p>17</p><p>(1.5%)*</p></td><td><p>13</p><p>(1.2%)**</p></td><td><p>50</p><p>(4.4%)</p></td></tr><tr><td><p>Symptomatic recurrent PE</p></td><td><p>6</p><p>(0.5%)</p></td><td><p>6</p><p>(0.5%)</p></td><td><p>19</p><p>(1.7%)</p></td></tr><tr><td><p>Symptomatic recurrent DVT</p></td><td><p>9</p><p>(0.8%)</p></td><td><p>8</p><p>(0.7%)</p></td><td><p>30</p><p>(2.7%)</p></td></tr><tr><td><p>Fatal PE/death where PE cannot be ruled out</p></td><td><p>2</p><p>(0.2%)</p></td><td><p>0</p></td><td><p>2</p><p>(0.2%)</p></td></tr><tr><td><p>Symptomatic recurrent VTE, MI, stroke, or non-CNS systemic embolism</p></td><td><p>19</p><p>(1.7%)</p></td><td><p>18</p><p>(1.6%)</p></td><td><p>56</p><p>(5.0%)</p></td></tr><tr><td><p>Major bleeding events</p></td><td><p>6</p><p>(0.5%)</p></td><td><p>5</p><p>(0.4%)</p></td><td><p>3</p><p>(0.3%)</p></td></tr><tr><td><p>Clinically relevant non-major bleeding</p></td><td><p>30</p><p>(2.7)</p></td><td><p>22</p><p>(2.0)</p></td><td><p>20</p><p>(1.8)</p></td></tr><tr><td><p>Symptomatic recurrent VTE or major bleeding (net clinical benefit)</p></td><td><p>23</p><p>(2.1%)<sup>+</sup></p></td><td><p>17</p><p>(1.5%)<sup>++</sup></p></td><td><p>53</p><p>(4.7%)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>* p&lt;0.001(superiority) Banoriv 20 mg od vs ASA 100 mg od; HR=0.34 (0.20&ndash;0.59)</p><p>** p&lt;0.001 (superiority) Banoriv 10 mg od vs ASA 100 mg od; HR=0.26 (0.14&ndash;0.47)</p><p><sup>+&nbsp;</sup>Banoriv 20 mg od vs. ASA 100 mg od; HR=0.44 (0.27&ndash;0.71), p=0.0009 (nominal)</p><p><sup>++</sup>&nbsp;Banoriv 10 mg od vs. ASA 100 mg od; HR=0.32 (0.18&ndash;0.55), p&lt;0.0001 (nominal)</p></td></tr></tbody></table><p>In addition to the phase III EINSTEIN program, a prospective, non-interventional, open-label cohort study (XALIA) with central outcome adjudication including recurrent VTE, major bleeding and death has been conducted. 5,142 patients with acute DVT were enrolled to investigate the long-term safety of rivaroxaban compared with standard-of-care anticoagulation therapy in clinical practice. Rates of major bleeding, recurrent VTE and all-cause mortality for rivaroxaban were 0.7%, 1.4% and 0.5%, respectively. There were differences in patient baseline characteristics including age, cancer and renal impairment. A pre-specified propensity score stratified analysis was used to adjust for measured baseline differences but residual confounding may, in spite of this, influence the results. Adjusted hazard ratios comparing rivaroxaban and standard-of-care for major bleeding, recurrent VTE and all-cause mortality were 0.77 (95% CI 0.40 - 1.50), 0.91 (95% CI 0.54 - 1.54) and 0.51 (95% CI 0.24 - 1.07), respectively.</p><p>These results in clinical practice are consistent with the established safety profile in this indication.</p><p><em><u>Paediatric population</u></em></p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with Banoriv in one or more subsets of the paediatric population in the treatment of thromboembolic events. The European Medicines Agency has waived the obligation to submit the results of studies with Banoriv in all subsets of the paediatric population in the prevention of thromboembolic events (see section 4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Rivaroxaban is rapidly absorbed with maximum concentrations (C<sub>max</sub>) appearing 2 - 4 hours after tablet intake.</p><p>Oral absorption of rivaroxaban is almost complete and oral bioavailability is high (80 - 100%) for the 2.5mg and 10 mg tablet dose, irrespective of fasting/fed conditions. Intake with food does not affect rivaroxaban AUC or C<sub>max</sub>&nbsp;at the 2.5mg and 10 mg dose. Rivaroxaban 2.5mg and 10 mg tablets can be taken with or without food. Rivaroxaban pharmacokinetics are approximately linear up to about 15 mg once daily. At higher doses rivaroxaban displays dissolution limited absorption with decreased bioavailability and decreased absorption rate with increased dose. This is more marked in fasting state than in fed state. Variability in rivaroxaban pharmacokinetics is moderate with inter-individual variability (CV %) ranging from 30 % to 40 %, apart from on the day of surgery and the following day when variability in exposure is high (70 %).</p><p>Absorption of rivaroxaban is dependent on the site of its release in the gastrointestinal tract. A 29% and 56% decrease in AUC and C<sub>max</sub>&nbsp;compared to tablet was reported when rivaroxaban granulate is released in the proximal small intestine. Exposure is further reduced when rivaroxaban is released in the distal small intestine, or ascending colon. Therefore, administration of rivaroxaban distal to the stomach should be avoided since this can result in reduced absorption and related rivaroxaban exposure.</p><p>Bioavailability (AUC and C<sub>max</sub>) was comparable for 20 mg rivaroxaban administered orally as a crushed tablet mixed in apple puree, or suspended in water and administered via a gastric tube followed by a liquid meal, compared to a whole tablet. Given the predictable, dose-proportional pharmacokinetic profile of rivaroxaban, the bioavailability results from this study are likely applicable to lower rivaroxaban doses.</p><p><u>Distribution</u></p><p>Plasma protein binding in humans is high at approximately 92 % to 95 %, with serum albumin being the main binding component. The volume of distribution is moderate with V<sub>ss</sub>&nbsp;being approximately 50 litres.</p><p><u>Biotransformation and elimination</u></p><p>Of the administered rivaroxaban dose, approximately 2/3 undergoes metabolic degradation, with half then being eliminated renally and the other half eliminated by the faecal route. The final 1/3 of the administered dose undergoes direct renal excretion as unchanged active substance in the urine, mainly via active renal secretion.</p><p>Rivaroxaban is metabolised via CYP3A4, CYP2J2 and CYP-independent mechanisms. Oxidative degradation of the morpholinone moiety and hydrolysis of the amide bonds are the major sites of biotransformation. Based on&nbsp;<em>in vitro</em>&nbsp;investigations rivaroxaban is a substrate of the transporter proteins P-gp (P-glycoprotein) and Bcrp (breast cancer resistance protein).</p><p>Unchanged rivaroxaban is the most important compound in human plasma, with no major or active circulating metabolites being present. With a systemic clearance of about 10 l/h, rivaroxaban can be classified as a low-clearance substance. After intravenous administration of a 1 mg dose the elimination half-life is about 4.5 hours. After oral administration the elimination becomes absorption rate limited. Elimination of rivaroxaban from plasma occurs with terminal half-lives of 5 to 9 hours in young individuals, and with terminal half-lives of 11 to 13 hours in the elderly.</p><p><u>Special populations</u></p><p><em>Gender</em></p><p>There were no clinically relevant differences in pharmacokinetics and pharmacodynamics between male and female patients.</p><p><em>Elderly population</em></p><p>Elderly patients exhibited higher plasma concentrations than younger patients, with mean AUC values being approximately 1.5 fold higher, mainly due to reduced (apparent) total and renal clearance. No dose adjustment is necessary.</p><p><em>Different weight categories</em></p><p>Extremes in body weight (&lt; 50 kg or &gt; 120 kg) had only a small influence on rivaroxaban plasma concentrations (less than 25 %). No dose adjustment is necessary.</p><p><em>Inter-ethnic differences</em></p><p>No clinically relevant inter-ethnic differences among Caucasian, African-American, Hispanic, Japanese or Chinese patients were observed regarding rivaroxaban pharmacokinetics and pharmacodynamics.</p><p><em>Hepatic impairment</em></p><p>Cirrhotic patients with mild hepatic impairment (classified as Child Pugh A) exhibited only minor changes in rivaroxaban pharmacokinetics (1.2 fold increase in rivaroxaban AUC on average), nearly comparable to their matched healthy control group. In cirrhotic patients with moderate hepatic impairment (classified as Child Pugh B), rivaroxaban mean AUC was significantly increased by 2.3 fold compared to healthy volunteers. Unbound AUC was increased 2.6 fold. These patients also had reduced renal elimination of rivaroxaban, similar to patients with moderate renal impairment. There are no data in patients with severe hepatic impairment.</p><p>The inhibition of factor Xa activity was increased by a factor of 2.6 in patients with moderate hepatic impairment as compared to healthy volunteers; prolongation of PT was similarly increased by a factor of 2.1. Patients with moderate hepatic impairment were more sensitive to rivaroxaban resulting in a steeper PK/PD relationship between concentration and PT.</p><p>Banoriv is contraindicated in patients with hepatic disease associated with coagulopathy and clinically relevant bleeding risk, including cirrhotic patients with Child Pugh B and C (see section 4.3).</p><p><em>Renal impairment</em></p><p>There was an increase in rivaroxaban exposure correlated to decrease in renal function, as assessed via creatinine clearance measurements. In individuals with mild (creatinine clearance 50 - 80 ml/min), moderate (creatinine clearance 30 - 49 ml/min) and severe (creatinine clearance 15 - 29 ml/min) renal impairment, rivaroxaban plasma concentrations (AUC) were increased 1.4, 1.5 and 1.6 fold respectively. Corresponding increases in pharmacodynamic effects were more pronounced. In individuals with mild, moderate and severe renal impairment the overall inhibition of factor Xa activity was increased by a factor of 1.5, 1.9 and 2.0 respectively as compared to healthy volunteers; prolongation of PT was similarly increased by a factor of 1.3, 2.2 and 2.4 respectively. There are no data in patients with creatinine clearance &lt; 15 ml/min.</p><p>Due to the high plasma protein binding rivaroxaban is not expected to be dialysable.</p><p>Use is not recommended in patients with creatinine clearance &lt; 15 ml/min. Banoriv is to be used with caution in patients with creatinine clearance 15 - 29 ml/min (see section 4.4).</p><p><u>Pharmacokinetic data in patients</u></p><p>In patients receiving rivaroxaban for prevention of VTE 10 mg once daily the geometric mean concentration (90% prediction interval) 2 - 4 h and about 24 h after dose (roughly representing maximum and minimum concentrations during the dose interval) was 101 (7 - 273) and 14 (4 - 51) &mu;g/l, respectively.</p><p><u>Pharmacokinetic/pharmacodynamic relationship</u></p><p>The pharmacokinetic/pharmacodynamic (PK/PD) relationship between rivaroxaban plasma concentration and several PD endpoints (factor Xa inhibition, PT, aPTT, Heptest) has been evaluated after administration of a wide range of doses (5 - 30 mg twice a day). The relationship between rivaroxaban concentration and factor Xa activity was best described by an E<sub>max</sub>&nbsp;model. For PT, the linear intercept model generally described the data better. Depending on the different PT reagents used, the slope differed considerably. When Neoplastin PT was used, baseline PT was about 13 s and the slope was around 3 to 4 s/(100 &micro;g/l). The results of the PK/PD analyses in Phase II and III were consistent with the data established in healthy subjects. In patients, baseline factor Xa and PT were influenced by the surgery resulting in a difference in the concentration-PT slope between the day post-surgery and steady state.</p><p><u>Paediatric population</u></p><p>Safety and efficacy have not been established for children and adolescents up to 18 years.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, single dose toxicity, phototoxicity, genotoxicity, carcinogenic potential and juvenile toxicity.</p><p>Effects observed in repeat-dose toxicity studies were mainly due to the exaggerated pharmacodynamic activity of rivaroxaban. In rats, increased IgG and IgA plasma levels were seen at clinically relevant exposure levels.</p><p>In rats, no effects on male or female fertility were seen. Animal studies have shown reproductive toxicity related to the pharmacological mode of action of rivaroxaban (e.g. haemorrhagic complications). Embryo-foetal toxicity (post-implantation loss, retarded/progressed ossification, hepatic multiple light coloured spots) and an increased incidence of common malformations as well as placental changes were observed at clinically relevant plasma concentrations. In the pre- and post-natal study in rats, reduced viability of the offspring was observed at doses that were toxic to the dams.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="0" cellpadding="0" style="width:402px"><tbody><tr><td style="vertical-align:top"><p>Active Ingredients</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rivaroxaban</p></td><td style="vertical-align:top"><p>10.000</p></td></tr><tr><td style="vertical-align:top"><p>Excipients</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Lactose BP 200</p></td><td style="vertical-align:top"><p>89.000</p></td></tr><tr><td style="vertical-align:top"><p>Avicel PH 101</p></td><td style="vertical-align:top"><p>80.000</p></td></tr><tr><td style="vertical-align:top"><p>Hydroxypropyl Methylcellulose</p></td><td style="vertical-align:top"><p>8.000</p></td></tr><tr><td style="vertical-align:top"><p>Sodium Lauryl Sulphate</p></td><td style="vertical-align:top"><p>6.000</p></td></tr><tr><td style="vertical-align:top"><p>Croscarmellose Sodium Type-A</p></td><td style="vertical-align:top"><p>6.000</p></td></tr><tr><td style="vertical-align:top"><p>Magnesium Stearate</p></td><td style="vertical-align:top"><p>1.000</p></td></tr><tr><td style="vertical-align:top"><p>Coating Materials</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hydroxypropyl Methyl Cellulose</p></td><td style="vertical-align:top"><p>3.900</p></td></tr><tr><td style="vertical-align:top"><p>Titanium Dioxide Pharma Grade</p></td><td style="vertical-align:top"><p>1.200</p></td></tr><tr><td style="vertical-align:top"><p>Purified Talc</p></td><td style="vertical-align:top"><p>0.240</p></td></tr><tr><td style="vertical-align:top"><p>Polyethylene Glycol MW 6000</p></td><td style="vertical-align:top"><p>0.600</p></td></tr><tr><td style="vertical-align:top"><p>Iron Oxide Red</p></td><td style="vertical-align:top"><p>0.060</p></td></tr><tr><td style="vertical-align:top"><p>Purified Water BP</p></td><td style="vertical-align:top"><p>Qs.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 Months/2 Years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Reel PVC/PE/PVDC</p><p>Each pack contains 10 film coated tablets.</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements for disposal.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SPIMACO
AlQassim pharmaceutical plant
Saudi Pharmaceutical Industries &
Medical Appliance Corporation.
Saudi Arabia

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                June 2018
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>